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Abstract 
Characterization of Rat Pulmonary Carboxyl esterase 
By Timothy 1. Wallace, Ph.D .  
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 1 999. 
Major Director: W. McLean Grogan, Professor, Department of Biochemistry and Molecular 
Biophysics 
The 1 839  bp cDNA for rat pulmonary carboxyl esterase was cloned by reverse transcription 
polymerase chain reaction (RT PCR) from total rat lung RNA using specific primers derived 
from the 5' and 3' untranslated regions of rat hepatic cholesteryl ester hydrolase (CEH). '  The 
unique cDNA was sequenced and found to have 99% homology with hepatic CEH. This 
homology extends to the predicted amino acid sequences which show only six amino acid 
residue differences in the coding region: three conserved and three nonconserved changes. 
However, the catalytic activitites of the two proteins are dramatically different. While CEH 
hydrolyzes cholesterol oleate, the pulmonary carboxylesterase has no activity towards this 
substrate. The active recombinant lung carboxyl esterase was purified using a baculovirus 
expression system. The substrate specifities were determined using p-nitrophenyl acetate, p-
nitrophenyl caprylate and cholesterol oleate. Also, the KM, V max and pH optima were 
xi 
determined for each substrate. Comparison of the substrate specificities of the recombinant 
pulmonary carboxylesterase with the recombinant CEH further establish the critical role of 
the six amino acid residues in determining the differences in the catalytic activities of these 
two proteins. Cumulative mutations were made in the lung carboxyl esterase sequence to 
those of the hepatic CEH sequence, in order to determine the role(s) of these six amino acid 
residues in conferring cholesterol oleate hydrolytic activity. These studies showed that Gln1 86 
is vital for activity towards hydrophilic substrates, while the region around amino acid residue 
500 consisting of Ser491 , Lys492, AsnS06 and AsnS04 may be responsible for the absence of 
catalytic activity towards hydrophobic substrates. 
Introduction 
Carboxylesterases comprise a highly homologous multi gene family of serine esterases, 
the gene products of which are localized in the endoplasmic reticulum and cytosol in cells of 
many tissues. These highly homologous enzymes catalyze the hydrolysis of many endogenous 
compounds such as long- and short-chain acylglycerols, long-chain acylcarnitine, and long­
chain acyl-CoA esters; however, specifically defined physiological functions have yet to be 
clarified. Carboxylesterases also catalyze the hydrolysis of many exogenous amide and ester 
linkages. They are involved in the detoxification or metabolic activation of many drugs and 
prod rugs, environmental toxins and carcinogens. Many carboxylesterases have been 
characterized biochemically based on their substrate specificities, enzymatic inhibition -and 
subcellular localization (Mentlein et ai, 1 980; Robbi and Beaufay, 1 983 ; Van Zutphen, 1 983 ;  
Mentlein et ai, 1 987; Hosokawa et ai, 1 990; Morgan et ai, (994). However, due to the high 
degree of similarity between the isoforms of these enzymes, specific properties of individual 
enzymes are difficult to discern. More recently, some carboxylesterases have been 
characterized at the molecular level which has allowed for more specific characterization of 
individual gene products (Long et ai, 1 988; Takagi et ai, 1 988; Robbi et ai, 1 990; Riddles et 
ai, 1 99 1 ;  Shibata et ai, 1 993;  Robbi and Beaufay, 1 994; Yan et ai, 1 994; Yan et ai, 1 995; 
Ghosh et ai, 1 995; Yan et ai, 1 995; Robbi et ai, 1 996). As the molecular characteristics of 
2 
the individual gene products are compared to the biochemical characteristics of the 
traditionally purified enzymes a clearer picture can be seen of a complex family of enzymes 
that shares a high degree of sequence homology whose isoforms may differ greatly in 
substrate specificities and therefore in their potential physiological functions 
Carboxylesterases are hormonally regulated and it is possible that posttranslational 
modifications, such as glycosylation or phosphorylation, may contribute to the differential 
substrate specificities of the individual isoforms that are otherwise quite structurally similar. 
The liver carboxylesterases are the best characterized, however, the importance of the 
pulmonary carboxyl est erases in surfactant turnover and in organophosphorus detoxification 
is becoming clear. 
Carboxylic acid esterases (EC 3 .  1 .  1 )  are a diverse class of enzymes which typically 
hydrolyze a broad range of hydrophilic and hydrophobic oxoesters. Early attempts to classify 
these enzymes as lipases, with lipophilic substrates, or est erases, with hydrophilic substrates, 
were confounded by broad specificities and the complexities of interfacial catalysis. Presently, 
the difference in classification between esterases and lipases remains unclear, however, and 
often times the distinction is made based on the length of the ester substrate. Lipases 
preferentially hydrolyze esters oflonger-chain fatty acids, while esterases hydrolyze esters of 
shorter-chain fatty acids. This distinction persists in some functional classifications. Although 
the broad specificity esterases are rigorously classified as carboxylesterases (EC 3 .  1 .  1 . 1 ), 
association with physiological function often predates determination of substrate specificities, 
resulting in classifications such as hormone-sensitive tryglyceride lipase (EC 3 .  1. 1 . 3 )  
3 
(Fredrikson et ai, 1 98 1 )  retinol-palmitate hydrolase (EC 3 . 1 . 1 . 2 1  )(Prystowsky et ai, 1 98 1 ), 
and cholesterol esterase (EC 3 . 1 . 1 . 1 3  )(Gallo et ai, 1 978). While this terminology remains 
useful in functional contexts, it overstates the intrinsic specificity of the enzymes and may not 
correspond to actual physiological function, especially in the case of intracellular 
carboxylesterases. 
Physiological Function 
The physiological functions of the carboxylesterases remain mostly undefined. These 
highly homologous enzymes catalyze the hydrolysis of many endogenous compounds such 
as long- and short-chain acylglycerols, long-chain acylcarnitine, and long-chain acyl-CoA 
esters (Alexson et ai, 1 993; Tsuj ita et ai, 1 993), indicating their potential importance in lipid 
metabolism. In both the mouse (Krishnasamy et ai, 1 997) and the rat (Gross et ai, 1 997), a 
lung surfactant convertase has been shown to convert one highly surface active isoform of 
alveolar surfactant, tubular myelin, to a less surface active isoform, small vesicular fotm, 
destined for re-uptake and hence recycling by alveolar type I I  cells. This 68kD surfactant 
convertase has recently been classified as a carboxylesterase (Barr et ai, 1 998), however its 
definitive physiological role remains unclear. Potential substrates in alveolar surfactant include 
phospholipids, triglycerides, cholesterol esters, and the thioester linkage in surfactant protein 
C (Krishnasamy et ai, 1 997; Gross et ai, 1 997; Barr et ai, 1 998), which are all potential 
substrates for carboxylesterases. Specifically defined physiological functions have been 
thoroughly described for only two carboxylesterases: retinyl ester hydrolase and hepatic 
cholesteryl ester hydrolase. Retinyl ester hydrolase catalyzes the hydrolysis of retinyl esters 
4 
in the liver and is therefore important in the body's overall vitamin A homeostasis (Sun el ai, 
1 997). Cholesteryl ester hydrolase plays an established compensatory role in the mechanism 
of cholesterol homeostasis in the liver (Ghosh el ai, 1 995) .  Neutral cholesteryl ester 
hydrolase is the key enzyme required for releasing the pool of metabolically active free 
cholesterol from stores of cholesterol esters, providing substrate for bile acid synthesis and 
for biliary secretion of cholesterol (Ghosh el aI, 1 995) .  
Xenobiotic Metabolism 
Carboxylesterases also catalyze the hydrolysis of many xenobiotics containing amide, 
thioester or ester linkages and thereby play an important role in drug metabolism and in the 
detoxification of many harmful chemicals present in the environment. Ester derivatives of 
therapeutically active prodrugs are utilized to improve solubility, absorption, bioavailability 
and in some cases to extend duration of action. Carboxylesterases have been shown- to 
activate the cholesterol-lowering prodrug lovastatin (Tang and Kalow, 1 995), the 
antiasthmatic terbutalin (Leinweber, 1 987), the antipsoriasis drug anthracen- I ,8,  9-thiol 
(Wiegrebe el ai, 1 984), and the long-acting neuroleptic prodrug haloperidol decanoate 
(Nambu el ai, 1 987). The anticancer prodrugs KW -2 1 89 (Ogasawara el ai, 1 994) and CPT­
I I (Tsuj i  el aI, 1 99 1 ;  Slatter el ai, 1 997; Kojima el ai, 1 998) are also activated to their 
anti tumorigenic forms by carboxylesterases. Aspirin (White el aI, 1 994), capsaicin (Park and 
Lee, 1 994), meperidine, butanilicaine, clofibrate and isocarboxazide (Dueker el aI, 1 99 1 ), are 
all drugs that are hydrolyzed to their inactive forms by carboxylesterases. Carboxylesterases 
also contribute to the nonoxidative ethanol metabolism in various organs (Tsujita and Okuda, 
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1 992) and to the detoxification of cocaine to benzoylecgonine (Dean et ai, 1 995). Also, the 
detoxification of organophosphorus compounds such as sarin and soman is catalyzed by 
carboxylesterases. 
Tissue Distribution 
There have been a number of studies showing that various carboxylesterases are 
present in a wide variety of tissues in a number of different species (Heymann, 1 980; 
Heymann, 1 982; Satoh, 1 987). Mammalian carboxylesterases have been studied in liver 
(Ghosh and Grogan, 1 99 1 ), lcidney (Tsujita et ai, 1 988), small intestine (Inoue et ai, 1 979; 
Morgan et ai, 1 994), pancreas (Lombardo et ai, 1 980; Bhat and Brockman, 1 98 1 ), plasma 
(Van Lith et ai, 1 993;  McCracken et ai, 1 993), lymphocytes (Treves et ai, 1 983), brain 
(Hojring and Svensmark, 1 977), adipose tissue (Tsujita et ai, 1 982; Tsujita and Okuda, 1 992), 
thymus (Gilhus, 1 983), testis (Yan et ai, 1 995), heart (Dean et ai, 1 995), lung (Gaustad et ai, 
1 99 1 )  and slcin (Nomeir et ai, 1 989). The highest abundance of carboxylesterases is found 
in the liver and testis, with a substantial amount in the lung and lcidney. The carboxylesterase 
found in the plasma is, in all likelihood, synthesized in the liver and then secreted into the 
circulation via the golgi apparatus (Murakami et ai, 1 993) .  Carboxylesterases are 
predominantly found in the endoplasmic reticulum, but have been shown to be present in both 
the endoplasmic reticulum and/or cytosol depending upon the tissue under investigation In 
the liver, carboxylesterases have been characterized from both the microsomal (Hosokawa 
et ai, 1 987) and cytosolic fractions (Ghosh and Grogan, 1 992; Natarajan et ai, 1996;Ghosh 
et ai, 1 998) where they have been shown to be involved in hepatic cholesterol homeostasis 
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in both in vitro and in vivo studies. In the lung, the carboxylesterases to date have been 
characterized from the cytosol (Gaustad et aI, 1 99 1 ;  Munger et aI, 1 99 1 ) . Cytosolic 
carboxyl esterase activity has also been demonstrated in the brain (Yamada et aI, 1 995) .  The 
existence of carboxylesterases in capillary endothelial cells in the brain supports the enzyme's 
potential role in protecting the central nervous system from exogenous toxic esters, and may 
be a component of the blood brain barrier (Yamada et aI, 1 994). 
Hormonal Regulation 
Both male and female rats contain multiple carboxylesterases with varying substrate 
specificities (Hosokawa et aI, 1 987). In castrated male rats the carboxyl esterase activities 
towards p-nitrophenyl acetate and malathion were lowered (Hosokawa et aI, 1 984). This 
decrease in activity was increased when testosterone propionate was administered to the 
castrated rats, indicating a regulation by gonadal hormones. Furthermore, adrenalectomy 
significantly decreased hepatic malathion and p-nitrophenyl acetate hydrolase activities in 
castrated male rats compared to normal rats (Hosokawa et aI, 1 985) .  The administration of 
testosterone propionate did not restore the carboxylesterase activity in the adrenalectomized 
castrated rats. However, the administration of the active metabolite of testosterone, 5a­
dihydrotestosterone, increased the carboxyl esterase activity toward p-nitrophenyl acetate and 
malathion. There is a substrate-dependent change in the carboxyl esterase activity in 
ovariectomized female rats (Hosokawa et aI, 1 984). There is an increase in activity towards 
p-nitrophenyl acetate and malathion and a decrease in activity towards acetanilide and 
isocarboxazid. Upon the administration of estradiol benzoate to the ovariectomized female 
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rats, the p-nitrophenyl acetate and malathion activities were decreased, indicating the 
inhibition of either the synthesis or activity of carboxylesterases by estrogen (Hosokawa et 
ai, 1 987). 
The regulation of hepatic microsomal carboxyl esterase activity by pituitary hormones 
has also been studied. Intraventricular injections of �-endorphin into male rats decreased 
hepatic carboxyl esterase activity while the administration of adrenocorticotropic hormone had 
no affect on the level of hepatic microsomal carboxyl esterase activity (Satoh and Hosokawa, 
1 998). In hypophysectomized male rats, hepatic carboxylesterases showed substrate­
dependent changes. There was a decrease in malathion and p-nitrophenyl acetate activities 
and an increase in the isocarboxazid activity (Hosokawa and Satoh, 1 988).  The 
administration of human growth factor to the hypophysectomized rats decreased the hepatic 
microsomal carboxyl esterase activity, while the subcutaneous injection of prolactin to-the 
hypophysectomized rats showed substrate-dependent changes in hepatic carboxyl esterase 
activity, indicating the regulation of hepatic microsomal carboxyesterases by some pituitary 
hormones (Hosokawa and Satoh, 1 988). The effects of this regulation vary with the 
individual isozymes of carboxylesterases. 
Glucocorticoids also have a regulatory effect on hepatic carboxylesterases (Hosokawa 
et ai, 1 993;  Ghosh et ai, 1 998). The administration of dexamethasone dose-dependently 
increased isocarboxazid hydrolase activity, while activity towards p-nitrophenylacetate 
decreased. Betamethasone, methylprednisolone, and pregnenolone 1 6a-carbonitrile increases 
isocarboxazid hydrolase activity (Hosokawa e/ ai, 1 993) .  Transcriptional activation was 
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shown for hepatic cholesteryl ester hydrolase after the administration of L-thyroxine and 
dexamethasone (Ghosh et ai, 1 998). Preliminary studies also showed a 30% decrease in 
hepatic cholesteryl ester hydrolase mRNA levels in thyroidectomized and hypophysectomized 
rats indicating a direct transcriptional regulation of the CEH gene by hormones. The 
hormonal regulation of hepatic cholesteryl ester hydrolase is further supported by the 
presence of functional glucocorticoid and L-thyroxine response elements in the cholesteryl 
ester hydrolase promotor (Natarajan et ai, 1 998). 
Biochemical Characterization 
Several investigators have characterized the liver carboxyl esterase family on the basis 
of their physical properties and relative specificities for a limited range of water soluble 
substrates, while focusing on their role in the metabolism of xenobiotics. Robbi and Beaufay 
have purified and characterized four rat liver est erases and named them according to their 
respective isoelectric points 5 .0, 5 . 5 ,  6. 1 and 6.4 (Robbi and Beaufay, 1 983). MentIein el al 
also used isoelectric points to distinguish five rat liver carboxylesterases (pI 5 .2, p I  5 .6, pI 
6.0, p I  6 .2  and pI  6.4) purified by ion exchange chromatography and isoelectric focusing 
(MentIein el ai, 1 980). MentIein et al later correlated the six carboxylesterases purified in 
their laboratories (Mentlein el ai, 1 987) with the "ES" system of genetic classification of rat 
esterases developed by van Zuptphen (Van Zuptphen, 1 983) .  Hosokawa el at purified three 
rat liver carboxylesterases using gel filtration, ion exchange and chromatofocusing column 
chromatographies (Hosokawa el ai, 1 987). Designated as RH 1 ,  RL 1 and RL2, these 
isozymes can be distinguished by their pI values of 6 .0, 6 .5  and 5 . 5 ,  respectively. Morgan el 
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al purified two rat liver carboxylesterases by anion-exchange chromatography and 
chromatofocusing and named them hydrolase A and B (Morgan et ai, 1 994) .  Gaustad et at 
purified three rat lung carboxyl est erases and characterized them based on their pI values: pI 
5 3 , pI 5 . 5  and pI  5 . 8  (Gaustad et ai, 1 99 1 ) . 
There have also been a number of carboxylesterases purified, characterized and named 
based on the specific substrates that they hydrolyze. Tsujita et al characterized a 
carboxylesterase and named it fatty acid ethyl ester synthase because it contributes to the 
nonoxidative ethanol metabolism in various organs (Tsujita and Okuda, 1 992). Tsujita et at 
also characterized a carboxylesterase from both the rat kidney and l iver and named it 
palmitoyl-CoA hydrolase because it hydrolyzed long-chain fatty acyl-CoA (Tsujita and 
Okuda, 1 993).  Alexson et al purified and characterized a carboxyl esterase from rat liver 
micro somes and named it microsomal acyl-CoA thioesterase because of its ability- to 
hydrolyze myristoyl-CoA to myristate and CoASH (Alexson et ai, 1 993) .  
There have also been two carboxylesterases characterized based on their physiological 
functions. Sun et al purified and characterized a carboxylesterase from rat liver and named 
it retinyl ester hydrolase because it had a preference for retinyl palmitate as a substrate over 
triolein and cholesteryl oleate and because of its role in vitamin A homeostasis (Sun et ai, 
1 997). Ghosh et al purified and characterized a carboxyl esterase, cholesteryl ester hydrolase, 
which they have shown to have a known function in hepatic cholesterol homeostasis (Ghosh 
and Grogan, 1 99 1 ) . 
In an attempt to reconcile the overlapping results from these studies, Morgan et at 
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compared catalytic and physical properties o f  the carboxylesterases, including substrate 
specificity , KM, molecular weight and isoelectric point (Morgan et ai, 1 994) The 
carboxylesterases can seemingly be separated into two groups based on sequence homology. 
In group I there are similarities between hydrolase A, the pI  6 .0  esterase, the pI  6. 1 esterase, 
and esterase RHI. Other carboxylesterases that are similar to these categorized by Morgan 
et al are microsomal acyl CoA thioesterase, the lung carboxyl esterase pI 5 . 8, palmitoyl-CoA 
hydrolase, fatty acid ethyl ester synthase, ES-\ 0 and E- I .  In group 2, there are similarities 
between hydrolase B, pI 6 .2/6.4  esterase and esterase RL 1 .  
Biochemical Properties 
Molecular Weight 
All of the carboxylesterases characterized share common subunit molecular weights 
between 57 kDa and 66 kDa. Their quaternary association forms, however, vary greatly. 
RL I and RL2 purified by Hosokawa et al behave as monomers of 6 1  kDa, while RH I 
behaves as a trimer of about 1 80 kDa. Both hydrolase A and hydrolase B purified by Morgan 
et al behave as monomers of 57 kDa and 59 kDa, respectively. The lung carboxyl esterase pI 
5 .8 purified by Gaustad et ai, pI 6 .0 purfied by Mentlein et al and the pI 6 . 1 purified by Robbi 
and Beaufay behave as trimers of 1 80 kDa (Satoh and Hosokawa, 1 998). 
Substrate Specificity 
Table I shows the catalytic activities of some of the highly purified carboxylesterase 
isozymes towards a number of different substrates. The five carboxylesterases purified by 
Mentlein et al ( pI 5 .2, pI 5 .6, pI 6.0, pI 6.2 and pI 6.4) all show considerable activity towards 
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Table 1: Specific Activities (�mole/hr/mg) of various carboxylesterases towards various 
substrates. 
Enzyme p-nitrophenyl aectate methylbutyrate I-monooleoylglycerol 
pI 5 . 2  330  1 092 1 7  
pI 5 .6  1 344 1 536 95 
pI 6 .0 2664 1 5000 40 
pI 6 .2 5640 306 1 93 
pI 6 .4 7860 1 20 2 1 3  
RH I 2688 * * * *  * * * *  
RLI 4584 * * * *  * * * *  
RL2 250 * * * *  * * * *  
RL4 3 894 * * * *  * * * *  
FAEE * * * *  4024 39  
* * * *  indicates no  information available. 
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monooleylglycerol and monolaurylglycerol (Mentlein et ai, 1 987). p I  6 . 4  had the highest 
specific activity towards p-nitrophenyl acetate, in addition to l-monooleylglycerol. pI 6 .0 had 
the highest specific activities for both the short-chain aliphatic ester methylbutyrate as well 
as butanilicaine. pI 5 . 6  had the highest specific activity towards acetanilide. The three 
carboxylesterases purified by Hosokawa et al (Hosokawa et ai, 1 990) are also very different 
based on their substrate specificities. RL 1 shows the highest specific activity towards p­
nitrophenyl acetate, palmitoyl-CoA and malathion. RHI shows the highest specific activity 
towards butanilicaine and isocarboxazid .  Fatty acid ethyl ester synthase characterized by 
Tsujita et al showed the highest specific activity towards methyl butyrate (Tsujita and Okuda, 
1 992). Hepatic cholesteryl ester hydrolase purified and characterized by Ghosh et al 
hydroylyzed oleoyl esters of both cholesterol and glycerol, but activity was consistently higher 
with cholesteryl oleate (Natarajan et ai, 1 996). Natarajan et al also measured the catalytic 
activity with PNP-esters offatty acids of different chain lengths. Activity was the lowest with 
the water-soluble p-nitrophenyl acetate, which is efficiently hydrolyzed by other esterases 
including the pI 6 . 1 purified by Robbi and Beaufay (Robbi and Beaufay, 1 983) .  Cholesteryl 
ester hydrolase activity increased with chain length, peaked with the more lipophilic p­
nitrophenyl caprylate, and then declined gradually with increasing chain length >Cs. 
Nevertheless, activity was consistently higher with the more lipophilic esters than with p­
nitropheny acetate (Natarajan et ai, 1 996). 
Table 2 shows the kinetics of the hydrolysis of esters and amides by lung 
carboxylesterase pI 5 . 8  purified by Gaustad et al and hydrolase A and B purified by Morgan 
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Table 2: Kinetics o f  Hydrolysis ofp-nitrophenyl acetate: Lung C E  (Gaustad et al), hydrolase 
A and hydrolase B 
Enzyme KM (�M) Vmax (�Mole/hr/mg) 
lung CE [Gaustad et al] 60 1 07 
hydrolase A 25 1 32 
hydrolase B 400 1 08 
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el al. The high-affinity esterase hydrolase A exhibited a KM of 2 5  11M and a V max of 2 .2 
I1moVmg protein/min. for p-nitrophenyl acetate, and was detected in rat testis, lung, prostate 
and pancreas (Morgan el ai, 1 994). The low-affinity esterase hydrolase B exhibited a KM of 
400 11M and a V max of 1 . 8 I1mol/mg protein/min. for p-nitrophenyl acetate, and was detected 
in kidney, small intestine, lung, spleen, heart and brain. Gaustad el al calculated a KM of 60 
11M and a V max of 1 07 I1mol/mg protein/min. for p-nitrophenyl acetate for a carboxylesterase 
purified from lung cytosol (Gaustad el ai, 1 99 1 ) . 
Induction and Inhibition 
Carboxylesterases can be induced by a number of chemicals that induce the 
xenobiotic-metaboLizing cytochrome P450 isozymes. Phenobarbitol, Araclor 1 245, polycyclic 
aromatic hydrocarbons, aminopyrine, synthetic glucocorticoid, pregnenolone 1 6, (X­
carbonitrile and clofibrate all have been shown to induce the carboxylesterases (Satoh and 
Hosokawa, 1 998) .  
Carboxylesterases are inhibited by a number of compounds. 
Chlorodiflouroacetaldehyde or disulfram treatment has been shown to inhibit hepatic 
microsomal carboxylesterase activity. Nordihydroguaiaretic acid and its related ligands have 
been shown to inhibit carboxyl esterase activity. Bis-p-nitrophenylphosphate, tri­
orthocresylphosphate and di-isopropylflourophosphate are all serine esterase inhibitors and 
have been shown to inhibit carboxylesterase activity. Furthermore, organophosphorus 
compounds have been shown to irreversibly bind and inhibit carboxyl esterase activity by 
1 5  
forming a phosphoryl intermediate at the active site of the enzyme (Satoh and Hosokawa, 
1 998). 
Molecular Characterization 
The cDNAs of several carboxylesterases have been cloned, sequenced and expressed 
from various tissues (Long et ai, 1 988;  Takagi et ai, 1 988;  Robbi et ai, 1 990; Riddles et ai, 
1 99 1 ;  Shibata et ai, 1 993 ; Robbi and Beaufay, 1 994; Yan et ai, 1 994; Yan et ai, 1 995; Ghosh 
et ai, 1 995; Yan et ai, 1 995; Robbi et ai, 1 996). Yan et al cloned three carboxylesterases 
termed hydrolase A, hydrolase B and hydrolase C. Robbi and Beaufay cloned three 
carboxylesterases: pI 6 . 1 ,  palmitoyl-CoA hydrolase and ES-3 . Takagi et al cloned 
carboxylesterase E 1 from rat liver. Ghosh et al cloned hepatic cholesteryl ester hydrolase, 
and Long et al cloned a carboxyl esterase from rat liver. 
Based on cDNA sequence homology these carboxyesterases can be categorized into 
two groups. Group one consists of the hepatic cholesteryl ester hydrolase, hydrolase A and 
the pI 6 . 1 .  AIl of these sequences share 98% similarity. Group two consists of hydrolase B, 
hydrolase C and palmitoyl CoA hydrolase which also shares about 98% similarity. The 
similarity between the two groups is on the order of 73%. The cDNA cloned by Long et al 
does not fall into either of these two groups based on sequence. It shares 78% similarity with 
the group one sequences and about 73% similarity with the group two sequences. 
There are also some consensus sequence similarities of the predicted amino acid 
sequences within the two groups. Carboxylesterases belong to the family of serine esterases, 
which are characterized by a conserved catalytic triad (serine, histidine and an acidic residue). 
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As shown i n  Table 3 ,  domains associated with the catalytic triad are present i n  the all of the 
carboxylesterases cloned thus far. These conserved regions contain putative active site 
residues, namely ASpl l S in a SEDCLY motif, Ser21 in a GXSXG motif, Glu246 in an SES 
motif, and His466 in a GDHGD motif(Yan et aI, 1 994). These highly conserved residues have 
been identified as the targets for site-directed mutagenesis studies (Satoh and Hosokawa, 
1 998). Frey et al ( Frey et aI, 1 994) studied the formation of low-barrier hydrogen bonds 
between the active site His and the active site Glu in chymotrypsin and the resultant action 
ofthe nucleophilic attack by the P-OH group ofthe active site Ser on the acyl carbonyl group 
of the substrate. Satoh and Hosokawa applied this model to carboxylesterases and it is 
depicted in Figure 1 (Satoh and Hosokawa, 1 998) .  
Furthermore, there are four identical cysteine residues in the group one 
carboxylesterases corresponding to the four cysteine residues of the hepatic CEH (Ghoshet 
aI, 1 995), pI 6 . 1 esterase (Robbi et aI, 1 990), hydrolase A (Yan et aI, 1 995), the 
carboxylesterase cloned by Long et al (Long et aI, 1 988) and torpedo acetylcholinesterase, 
which is the parent protein of the serine esterases (Schumacher et aI, 1 986). It has been 
demonstrated that these cysteines pair to form internal disulfide bridges in human 
cholinesterase (Lockridge et aI, 1 987) In addition to these four cysteine residues, hydrolase 
B (Yan et aI, 1 994) and ES-4 (Robbi et aI, 1 996) contain a fifth cysteine and hydrolase C 
(Yan et aI, 1 995) contains a sixth cysteine not present in the group one carboxylesterases. 
It has been shown that N-glycosylation can have a profound effect on the specific 
Table 3: Comparison of conserved motifs in carboxylesterases. 
Enzyme 
Rat lung CE 
Rat hepatic CEH 
Rat pi 6.1 
Rat hydrolase A 
Rat hydrolase B 
Rat hydrolase C 
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Figure l� A proposed mechanism for the action of carboxylesterases. Mechanism of Frey et 
al (Frey et aI, 1994) and Hosokawa et al (Satoh and Hosokawa, 1998) amended to include 
cholesterol ester as the substrate. Frey et al studied the formation of low-barrier hydrogen 
bonds between the active site His and the active site acidic residue in chymotrypsin and (he 
resultant action of the nucleophilic attack by the P-OH group of the active site Ser on the acyl 
carbonyl group of the substrate. The carbonyl carbon of the ester substrate is attacked by \he 
nucleophilic active site serine, forming a covalent intermediate. The addition of water aids 
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activity of proteins (Kroetz et ai, 1 993) .  The group one carboxylesterases described above 
share two potential N-glycosylation sites. Asn79 and Asn489 of the hepatic cholesteryl ester 
hydrolase correspond to Asn61 and Asn471 , respectively in pI 6 . 1 esterase and hydrolase A. 
CEH contains one additional potential N-g1ycosylation site at Asn504 not present in the p1 6 . 1 
(Robbi et ai, 1 990) or hydrolase A (Yan et ai, 1 995) which might contribute to differences 
in substrate specificity. Hydrolase B (Yan et ai, 1 994), hydrolase C (Yan et ai, 1 995) and Es-
4 (Robbi et ai, 1 996) all contain one potential N-glycosylation site similar to the hepatic 
cholesteryl ester hydrolase at Asn61 It has been reported that Asnl of the hydrolase B (Yan 
et ai, 1 994) and hydrolase C (Yan et ai, 1 995) is a potential N-glycosylation site. However, 
due to the position of the proline residue in the motif Asn-Xaa-Ser/Thr where Xaa is Proline, 
it is highly unlikely that Asnl of these sequences is glycosylated (Bause, 1 983) .  The 
carboxylesterase cloned by Long et al contains four potential N-glycosylation sites, two.of 
which are not present in any other cloned carboxylesterase and are located just downstream 
of the second proposed disulfide bridge (Long et ai, 1 988) .  
Many carboxylesterases have been shown to be retained on the lumenal side of the 
endoplasmic reticulum (Robbi and Beaufay, 1 99 1 ) . Resident proteins of the lumen of the 
endoplasmic reticulum are continuously retrieved from an early golgi compartment by a 
receptor-mediated mechanism (Medda and Proia, 1 992). The sorting or retention sequence 
on these endoplasmic reticulum proteins is located at the C-terminus and was initially shown 
to be the tetrapeptide KDEL in mammalian cells (Munro and Pelham, 1 987). There are also 
a number of C-terminal tetrapeptide variations among the carboxylesterases that signal their 
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retention i n  the lumen o f  the endoplasmic reticulum. HVEL, HNEL, HTEL and RIEL all 
serve as suitable endoplasmic reticulum retention signals (Andres et ai, 1 990; Andres et ai, 
1 99 1 ;  Kaletta et ai, 1 998). Site-directed mutagenesis studies of this C-terminal tetrapeptide 
reveal that a number of variations of the KDEL sequence can retain a normally secreted 
protein in the lumen of the endoplasmic reticulum when the C-terminus is changed to match 
one of the retention signals (Haugejorden et ai, 1 99 1 ) .  The C-terminal sequences -EVX 
(X=S, N or Q) and -A VL reported by Mentlein et al (Mentlein et ai, 1 984) for pI 6 .4 and pI 
6. 1 esterasese, respectively, suggests that the C-terminal tetrapeptide may not apply to all the 
proteins of the lumen of the endoplasmic reticulum. The C-terminal tetrapeptide for the 
hepatic cholesteryl ester hydrolase cloned by Ghosh et al (Ghosh et ai, 1 995) is HVEL which 
has been shown to be a endoplasmic reticulum retention signal in other carboxylesterases. 
However, the hepatic cholesteryl ester hydrolase has been .shown to be cytosolic (Ghosh and 
Grogan, 1 992). 
As similar as the cDNAs of the members of each group of carboxylesterases are, 
minor sequence differences among the homologs within each subfamily of enzymes apparently 
account for substantial differences in their catalytic properties. In the group two 
carboxylesterases, hydrolase B and hydrolase C are 96% identical in nucleotide sequence and 
93% identical in amino acid sequence, yet the specific activity of recombinant hydrolase C in 
the hydrolysis ofp-nitrophenyl acetate was only 3% that of purified hydrolase B (Yan et ai, 
1 995). This observation is reinforced by the cloning and expression of the cDNA for 
cholesteryl ester hydrolase ( cholesterol esterase) which is highly homologous but not identical 
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with pI 6 . 1 esterase (Ghosh et ai, 1 995).  Although it is not yet known whether any of the 
other homologs have cholesterol esterase activity, the purified cholesteryl ester hydrolase 
differs substantially from pI 6 . 1 esterase in specificity for water soluble substrates (Natarajan 
et ai, 1 996). This underscores the importance of cloning , expression and characterization 
of single gene products in defining respective roles of the homologs within these subfamilies 
of est erases. 
Pulmonary Carboxylesterases 
Research to date on pulmonary carboxylesterases has been limited. Gaustad et al 
reported the purification and characterization of a carboxylesterase from rat lung that is 
inhibited by the organophosphorus compounds soman and sarin; however, they continually 
had very low yields of the enzyme after each purification ( 1 .0 mg proteinJ70 g lung tissue), 
which makes thorough studies into the nature and role of this enzyme difficult (Gaustad et ai, 
1 99 1 ) . Munger et al described a serine esterase released by human alveolar macrophages 
that is closely related to liver microsomal carboxyl esterase (Munger et ai, 1 99 1 ) . They also 
proposed a role for this enzyme in the detoxification of harmful xenobiotics. The inability to 
clone a full length cDNA from alveolar macrophage RNA limited the molecular 
characterization of the enzyme. 
Most characterization of pulmonary carboxylesterases has been based on xenobiotic 
metabolism with an emphasis on organophosphate detoxification. The acute toxicity of 
organophosphorus compounds in mammals is usually attributed to their irreversible inhibition 
of acetylcholinesterase (Brimblecombe et ai, 1 977). The function of acetylcholinesterase is 
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to terminate the action of the neurotransmitter acetylcholine at the junctions of cholinergic 
nerve endings. Organophosphorus compounds are highly toxic ester derivatives of 
phosphoric and phosphonic acid, that elicit their primary effects by phosphorylating or 
phosphonylating the serine hydroxyl at the active site of acetylcholinesterase (Gray, 1 984). 
The effects of acute intoxication by organophosphorus anticholinesterase agents are 
manifested by muscarinic and nicotinic signs and symptoms. The time of death after a single 
acute exposure may range from less than five minutes to nearly twenty four hours, depending 
upon the dose and route of exposure (Tayor, 1 99 1 ) . The cause of death is primarily 
respiratory failure, usually accompanied by a secondary cardiovascular component. 
Muscarinic, nicotinic and central nervous system actions all contribute to respiratory failure. 
Effects include laryngospasm, bronchoconstriction, increased tracheobronchial and salivary 
secretion compromised voluntary control of the diaphragm and intercostal muscles, and 
central respiratory depression. 
It has been shown that organophosphorus compounds react irreversibly with 
carboxylesterases, whose inhibition produces no physiological toxicity (Maxwell, 1 992) 
Therefore, carboxylesterases act as scavengers that reduce the amount of organophosphorus 
compound available to inhibit acetylcholinesterase. From the viewpoint of pharmacology and 
toxicology, the importance of carboxyl est erases for organophosphate detoxification appears 
to be primarily the result of the kinetics of organophosphorus absorption and distribution 
whereby the tissue carboxyl esterase that first encounters an organophosphorus compound is 
the carboxyl esterase that preferentially detoxifies it (Maxwell, 1 992). Furthermore, the 
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general relationship between the pattern of in vivo carboxyl esterase inhibition in tissues and 
the variation in the potentiation of lethality by carboxyl esterase inhibitors suggests that 
carboxyl esterase detoxification of highly toxic compounds such as sarin and soman is nearly 
completely accomplished by the carboxylesterase in plasma and lung (Maxwell, 1 992). 
Regardless of the difficulties in elucidating the role of such a heterogenous family 
enzymes as the carboxlesterases, many investigators in the field of xenobiotic metabolism 
agree that the lung plays a primary role in the detoxification of harmful organophosphorus 
agents (Fonnum et ai, 1 985;  Maxwell, 1 992; McCracken et ai, 1 993;  Reiner et ai, 1 993; F oth, 
1 995). Among all tissues that are permanently exposed to the environment, the lung is the 
largest-sized site of primary contact with air contaminated with vapors, aerosols and 
xenobiotic particles (Foth, 1 995) .  The lung also is in the unique position, in that not only 
does all inhaled material pass through the pulmonary epithelium before it can gain systemic 
access, but all compounds that are present in venous blood will enter the pulmonary 
circulation as well . Therefore, the endothelial surface of pulmonary tissue comes in close 
contact with all inhaled xenobiotics as well as those already present in the blood. As such, 
it is the pulmonary carboxyl esterase that serves as the primary detoxifying enzyme against 
inhaled organophosphorus agents and possibly plays a secondary role against these toxic 
agents already present in the circulation. 
The lung carboxyl esterase has recently been shown to have an important physiological 
significance as a putative surfactant convertase, playing a role in extracellular pulmonary 
surfactant metabolism (Krishnasamy et ai, 1 997). Pulmonary surfactant is a lipoprotein 
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secretion of the alveolar type I I  cell and is important for maintaining the volume stability of 
the lung (Clements, 1 957). Synthesized in type II cells and stored in secretory lamellar 
bodies, surfactant is secreted into the alveolar lining by exocytosis. Once in the alveolar liquid 
lining, the lamellar bodies convert into the aggregate tubular myelin .  This tubular myelin is 
the precursor of the phospholipid-containing alveolar surface layer responsible for lowering 
the surface tension of the lung-fluid interface during respiration. Also present in the alveolar 
surface layer are apoprotein-depleted vesicular structures that represent the products and 
remnants of the disassembly of lamellar bodies, tubular myelin and the phospholipid­
containing alveolar surface layer (Barr et ai, 1 998). The conversion of tubular myelin to the 
apoprotein-depleted vesicles is catalyzed by a surfactant convertase (Krishnasamy et ai, 
1 997). It has recently been shown that this convertase is a di-isopropylflourophosphate 
binding protein with a molecular weight of 72 kDa whose partial amino acid sequence 
matches identically with a member of the carboxyl esterase family of enzymes (Krishnasamy 
et ai, 1 997). 
Rationale for study 
Carboxylesterases are a family of ubiquitous enzymes that are present in many tissues 
whose functions to date have mainly been described in xenobiotic metabolism. With the 
exception of cholesteryl ester hydrolase and retinol-palmitate hydrolase, the physiological 
function of the carboxylesterases has yet to be determined. To date, hepatic carboxylesterases 
are the most well characterized, however it has been shown that there is a very high 
abundance of these proteins in various other tissues including lung. The importance of the 
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lung carboxylesterase has been shown in organophosphorus detoxification and its potential 
importance has been indicated in surfactant turnover. Thus, the pulmonary carboxylesterase 
plays a major role in pulmonary physiology. 
Carboxylesterases have a very high degree of overlapping substrate specificities that 
makes characterization of individual proteins difficult, if not impossible. Only nine 
carboxylesterases have been cloned, sequenced and characterized at the molecular level and 
the comparison of any two of these has not gone beyond sequence comparisons and simple 
substrate specificities. It is imperative that individual gene products are cloned, characterized 
and thoroughly compared with other molecularly characterized gene products, and that 
recombinant proteins are purified from these individually cloned cDNAs. This will enable 
thorough characterization of this highly homologous family of enzymes and ultimately lead 
to their differentiation from one another and to the determination of the specific physiological 
role or roles of these proteins. 
Specific objectives to be addressed are as follows: 
I .  Clone, sequence, express and localize the pulmonary carboxyl esterase and to 
determine, in vitro, its inhibition by organophosphorus compounds. 
2. Purify the recombinant pulmonary carboxyl esterase from the cloned cDNA using a 
baculovirus expression system. 
3 .  Mutate amino acid residues that differentiate the pulmonary carboxyl esterase from the 
hepatic CEH and determine the important residues responsible for the resultant shift 
in specificity from hydrophilic to hydrophobic substrates between the two proteins. 
Materials and Methods 
Preparation of total RNA from Lung tissue 
Total RNA was prepared from 0 .5  g offreshly isolated male Sprague Dawley rat lung. 
0 . 5  g oflung tissue was placed in 7 .5  ml of guanidine isothiocyanate solution (4 M guanidine 
isothiocyanate, 1 0  mM Tris-HCI, pH 7 .4, and 7% f3-mercaptoethanol) and N-Iauryl sarcosine 
was added to a fi nal concentration of 2%. The mixture was homogenized to break up the 
tissue completely. This suspension was passed through a 23-guage needle and underlayered 
with 5 . 7  M cesium chloride containing 1 0  mM EDT A (pH 7.4). Total RNA pellet obtained 
following centrifugation at 1 00,000 x g for 1 6  hrs. was washed twice with 1 00% ethanol, 
dissolved in DEPC-treated water and precipitated with two volumes of 1 00% ethanol in the 
presence of one-tenth volume of 3 M sodium acetate, pH 5 . 0  and stored at -20°C f0r 
overnight precipitation. Total RNA was pelleted by centrifugation at 1 2,000 x g for 30  min. ,  
redissolved in DEPC-treated water and quantified by measuring the absorbance at 260 nm. 
Reverse transcritpase polymerase chain reaction 
First strand cDNA was synthesized from 1 0 �g of total RNA from rat lung and oligo 
dT as a primer using the Superscript™ Preamplification System (GibcoBRL, Gaithersburg, 
MO) according to the manufacturer's instructions. A sense PCR primer, XHO, (5 '­
CTCGAGCTGTGGGCT ATTTGTTCCTTCCAC), corresponding to bases -25 to -2 of the 
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carboxyl esterase, hepatic CEH, cDNA with an Xho 1 site on the 5' end and an antisense 
primer, XBA, (5'-GCTCT AGAAGCAA T AAGGTT AAGT A TTTTCCC), corresponding to 
bases 1 828- 1 8 5 1  of the hepatic CEH cDNA with an Xba 1  site on the 5' end, were 
synthesized. A search of the GenEMBL database revealed that no matches for either primer 
were detected that would interfere with there intended use in PCR. The first strand ( 1 5%) 
product was used to amplify the target cDNA. The PCR mixture composed of 1 X PCR 
buffer (20 mM Tris-HCL, pH 8 .4/50 mM KCL), 1 mM dithiothreitol, 0 .2  mM dNTPs and 20 
pmoles of the hepatic-specific primers in a final volume of 1 00 III was used. MgCI2 ( 1 . 5  mM) 
was added separately to the reaction mix and overlaid with mineral oil, and then amplified 
with the Coy TempCycler I I ,  model 1 1  OS. Taq DNA (2 . 5  units ) polymerase was added after 
an initial 5 minute cycle at 94°C. The amplification profile consisted of denaturation at 94°C 
for 30 seconds, primer annealing at 55°C for 45 seconds and extension at nOc for 2 minutes. 
Cloning and sequencing of lung earboxylesterase eDNA 
The PCR product (42 ng) was used to ligate with 60 ng of pCR TM3 vector using the 
eukaryotic T A cloning kit ( Invitrogen, San Diego, CA), and the ligated plasmid was used to 
transform TOP I OF' cells, according to the manufacturer's instructions. Plasmid DNA was 
prepared from individual colonies and analyzed by restriction enzymes in order to isolate the 
recombinant plasmid with the insert in the correct orientation. Lung cDNA was sequenced 
by "oligo walking" using the ABI PRISM™ Dye Terminator Cycle Sequencing Ready 
Reaction Kit (perkin Elmer, Foster City,CA). Reaction mixtures (20111) were made with 450 
ng of the eukaryotic expression vector pCR™3 containing the correct insert, 8.0 III of the 
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terminator ready reaction mix (A-Dye Terminator, C-Dye Terminator, G-Dye Terminator, 
T-Dye Terminator, dITP, dATP, dCTP, dTTP, Tris-HCL pH 9.0, MgCI2, thermal stable 
pyrophosphatase, and AmpliTaq DNA Polymerase, FS), and 3 . 2  pmoles of either sense or 
antisense primers. Each reaction mixture was overlaid with one drop of mineral oil . The 
cycle sequencing profile consisted of denaturation at 96°C for 1 5  seconds, primer annealing 
at 50°C for 7 seconds, and extension at 60°C for 4 minutes repeated for 25 cycles. Centri-Sep 
spin columns (Princeton Separations, Inc . ,  Adelphia, NJ) were used according to the 
manufacturer's instructions to remove excess DyeDeoxyTM terminators from the completed 
DNA sequencing reactions. The reactions were analyzed on the Applied Biosystems DNA 
Sequencer 373 A. 
Confirmation of eDNA by alternative cloning 
The above experiment was repeated from a separate RNA preparation, and a second 
full length clone was obtained and sequenced as described above. Furthermore, using '5' 
RACE and RT PCR, three additional clones were obtained spanning the same region of 
cDNA that was sequenced from the first clone. The primers synthesized for this additional 
cloning, and the corresponding bases of the lung carboxyl esterase cDNA with which they 
match, are as follows: 
Antisense primers 
ASP3 (S'-TCAGAGATTTTCAGTGTTGG) corresponding to bases 1 1 53 - 1 1 72 
ASP4 (S'-CCAGGAGTTCATCCTCTGTC) corresponding to bases 864-883 
ASP l (S'-CCAGTGGGATGGTTCCTCTG) corresponding to bases 1 66 1 - 1 680 
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Sense primer 
SP2 (5 '-TTCAGCACAGGGGATGA) corresponding to bases 532-548 
RNA (3 flg) was used in the first strand synthesis which was carried out using the 
Superscript™ Preamplification System (GibcoBRL) as described above. The 5' RACE 
System for Rapid Amplification of cDNA Ends (GibcoBRL) was used according to the 
manufacturer's instructions in order to obtain a 1 000 bp 5' RACE clone. Primer ASP3 was 
used with the anchor primer supplied by the kit for amplification. The amplification profile 
consisted of denaturation at 94°C for 30 seconds, primer annealing at 49° C for 45 seconds 
and extension at nOc for 2 minutes. A 1 200 bp band was obtained, and a 1 fll aliquot of this 
amplification product was reamplified using the nested universal amplification primer (UAP) 
supplied by the kit and the nested antisense primer ASP4. The same amplification profile was 
repeated and a 1 000 bp band was obtained, cloned and sequenced as described above . Sense 
primer SP2 and antisense primer ASP I were used to amplifY a 950 bp intermediate band by 
RT PCR which was subsequently cloned and sequenced as described above. Finally, sense 
primer SP2 and antisense primer XBA were used to amplifY a 1 300 bp band which was cloned 
and sequenced as described in materials and methods. 
Eukaryotic expression system 
A 90% confluent monolayer of COS-7 cells was transfected in a 35mm twelve-well 
plate with the plasmid pCR3 containing the full length cDNA using lipofectamine (GffiCO­
BRL) according to the manufacturer's instructions. Control cells were mock transfected with 
lipofectamine alone. Plasmid DNA (2 J.1g) was incubated with 6 J.11 of lipofectamine in 750 
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III of serum-free medium for 30  minutes at room temperature to allow proper formation of 
the cationic liposomal complexes. The cells were washed once with serum-free medium. of 
Serum-free medium (750 Ill) was added to the plasmid DNAILipofectamine mixture, and the 
1 . 5  mI solution was overlaid on the cells. After a total of 48 hours of incubation, the cells 
were harvested in I ml of250 mM phosphate buffer, pH 7 .4 containing 250 mM sucrose and 
protease inhibitors, 2 mM 3-methyl propionate, 0 .5  mM benzoyl arginine and 5 mM 
benzamidine (Ghosh and Grogan, 1 99 1 ) .  The cell suspension was sonicated using Heat 
Systems Ultrasonic Processor, and the cell debris was removed by centrifugation at 1 0,000 
X g for 30 minutes at 4°C. The post-mitochondrial supernatant was assayed for 
carboxyl esterase activity. 
In situ hybridization 
Under pentobarbitol anesthesia, rats were transcardially perfused with heparinized 
phosphate buffered saline (PBS) ( 1 00 mM sodium phosphate, 1 50 mM NaCi.  pH 7.2;  PBS) 
followed by fixative consisting of 4% paraformaldehyde, 0. 1 % glutaraldehyde. The lungs 
were removed and fixed for an additional 24 hours with the same fixative, dehydrated and 
embedded in paraffin wax. Sections were cut ( 1 0  11m) and processed as follows: 
Paraffin sections were dewaxed in xylene and hydrated through graded ethanol 
concentrations to PBS. Permeabilization was carried out for 2 minutes in 0 .0 1  % Triton X-
1 00 in PBS. Sections were then treated with proteinase K ( I  Ilglml in 20 mM Tris-HCL-5 
mM EDT A) for 30 minutes at 37°C . The reaction was stopped by postfixation in buffered 
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4% paraformaldehyde for 15  minutes, followed by rinsing in PBS for 5 minutes. Sections 
were then acetylated with 0 .25% acetic anhydride in O. I M  triethanolamine for 1 0  minutes, 
dehydrated through graded ethanol solutions and air dried. 
The hybridization buffer contained 50% formamide, 4 X SSC, I X denhardt's 
solution, 1 0% dextran sulfate, 0.24 1lg/1-.t1 yeast RNA, 0.5 1lg/1l1 salmon sperm DNA, 1% 
sarcosyl, 2 .4 mg/rnl N�P04 and I pmole/ml of the biotin-labeled probe that is complimentary 
to the 5' PCR primer used to clone the rat lung carboxyl esterase described above. 
Hybridization buffer (500 Ill) was applied to each slide and covered with a PROBE-CLIP 
(Grace Bio-Labs, Sunriver Oregon) to prevent evaporation. Hybridization was carried out 
overnight in moist chambers at 3 7°C . After hybridization, the sections were washed 4 times 
in 0 .5  X SSC for I S  minutes at room temperature. Sections were then incubated at room 
temperature for I hour in blocking solution (PBS containing 1% normal goat serum, 0 1% 
Triton X- I 00, 5% non-fat dry milk solids). Sections were then incubated with rhodami'ne 
conjugated to streptavidin for I hour at room temperature. After 3 X 30 minute washes with 
PBS, slides were air dried and mounted in glycerol/N-propyl galate. Affinity labeling was 
visualized using the Meridian Instruments OPTIMA scanning confocal fluorescence 
microscope with 5 1 6  nm laser excitation and dual wavelength detection of emission. 
Northern blot analysis 
Total rat lung RNA ( 1 0  Ilg) was electrophoresed on a 0 .7% agarose gel in the 
presence offormaldehyde. The RNA was stained with ethidium bromide and the integrity of 
the isolated RNA was verified by the presence of 28S and 1 8 S  rRNA bands. The RNA was 
33 
transferred to a GENESCREEN membrane (NEN Research products, Boston MA) and 
hybridized with a nick-translated 32P-labeled full length lung carboxyl esterase cDNA 
according to the manufacturer's instructions. The blots were washed under low stringencies 
(2 X SSC + 0. 1 % SDS, at room temperature) and high stringencies (0 .2 X SSC + 0. 1 % SDS, 
at 60°C) .  Positive hybridization was detected by exposure to Kodak XAR-2 films for 1 6  
hours at -70°C. 
Inhibition of lung carboxylesterase by organophosphorus compounds 
The full length lung carboxylesterase cDNA was transfected into COS-7 cells as 
described above and 0 . 1 J.l.M, 1 .0 J.!M and 1 0 0 J.l.M paraoxon (Sigma Chemical Co., St. Louis, 
MO) was incubated with between 35 J.l.g and 45 J.l.g of protein for 1 5  minutes and 30 minutes 
at 3 7°C. To measure the decrease in activity towards p-nitrophenyl caprylate (Sigma 
Chemical Co. ,  St. Louis, MO), an aliquot of the supernatant was diluted with 200mM 
phosphate buffer, pH 7.4, 5mM p-mercaptoethanol and 80 mM potassium chloride, in a final 
volume of 1 ml. The reaction was started by the addition ofp-nitrophenyl caprylate to a final 
concentration ofO. 2mM and incubated at 3 7°C for 1 5  minutes. The release ofp-nitrophenol 
was monitored at 400 nm. 
Homologous recombination 
The 1 839  bp lung carboxylesterase cDNA was cut from the eukaryotic expression 
vector pCR3 with EcoR I and re-ligated into the multiple cloning site of the baculovirus 
transfer vector pBlueBacHis2B containing a 5' histidine tag. The orientation of the insert was 
confirmed using restriction enzyme analysis. The transfer vector containing the lung 
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carboxyl esterase eDNA was cotransfected with Bac-N-Blue viral DNA (Invitrogen, Carlsbad, 
CA) into SF9 cells and homologously recombined to form the recombinant virus containing 
the rat lung carboxyl esterase eDNA. The transfer vector contains sequences homologous to 
the lacZ gene and ORF I 629 sequences in Bac-N-Blue l inear DNA, which produced blue 
recombinant plaques. 
Purification of recombinant products 
A plaque assay was performed to purify recombinant products. Plates ( 1 00 mm) were 
seeded with 5 X 1 06 cells/plate ( 50% confluence). This allowed cells to double and form a 
confluent monolayer before the infection stopped the cell growth. Cells were infected with 
1 0-2, 1 0-3 and 1 0-4 dilutions of the transfection viral stock for one hour, after which time the 
medium was removed and the cell monolayer was overlayed with a mediumlagarose mix to 
"pin down" the infected monolayer. The chromogenic substrate 5-bromo-4-chloro-3-indoyl­
�-D-galactoside (X-gal) was incorporated into the medium at a final concentration bf 
1 50J..lg/ml to yield blue-green recombinant plaques. The plates were incubated until plaques 
formed (5- 1 0  days). 
peR analysis of recombinant virus 
PCR was used to determine the presence of the lung carboxyl esterase insert in the 
putative recombinant virus and to confirm the isolation of pure, recombinant plaques. Log­
phase Sf1:) cells were seeded at a density of 5 X 1 05 in a 1 2-well microtiter plate. Blue 
plaques were selected along with one wild-type plaque (control) and removed using a sterile 
pasteur pipet. Each plug containing the recombinant plaque was transferred to one of the 
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wells of  the microtiter plate and the plate was incubated at 27°C for 3 days. After 3 days, the 
wells were screened visually using the inverted microscope for the presence of occlusion 
bodies. Using only occ- wells and one occ+ well ( wild-type Bac-N-Blue control) the medium 
was pi petted gently to dislodge the cells. The suspension (0.75 mI) was removed and 
transferred to a sterile microcentrifuge tube. The microtiter plates were kept and incubated 
at 27°C until all of the cells lysed (5-7 days). The medium from each occ- well was then 
harvested and stored at 4°C. These were the purified viral stocks. The sample stored in the 
micro centrifuge was centrifuged at 5000 rpm for three minutes to pellet the cell debris. The 
viral DNA was extracted using phenol: chloroform and precipitated using sodium acetate and 
ethanol .  The DNA was resuspended in 1 0  III of sterile water. The isolated viral DNA (5 Ill) 
was used in a 50 III PCR reaction which was cycled in a thermocycler using the following 
parameters: Initial denaturation, one cycle at 94°e for two minutes; thirty cycles of 
denaturation, 94°C for two minutes, annealing, 55°C for two minutes and extension, noc for 
three minutes; final extension, one cycle at noe for seven minutes. 20111 of the PCR reaction 
was analyzed on a 1 %  agarose gel. 
Preparation of high-titer viral stocks 
Two flasks were seeded with 2 X 1 06 log-phase SF9 cells to which 20111 of the viral 
stock was added and incubated at 27°C until 80-90% of the cells lysed. The medium was 
harvested and added to a 500 mI suspension of log-phase SF9 cells seeded to a density of 1 . 8 
X 1 06 celis/mi. The culture was incubated for 7- 1 0  days at 27°C with constant stirring. 
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Progress of infection was monitored daily by withdrawing a sample and using the trypan blue 
exclusion assay to determine the extent of cell lysis. The culture was harvested when >90% 
of the cells had lysed. Virus titer was determined by preparing 1 0-fold serial dilutions of the 
viral stock. A plaque assay was done using the dilutions as described above. Plaques were 
counted and titer was determined as follows: ( I 1dilutions) X number of plaques=pfu/ml. 
Time course expression of recombinant protein 
A time course of expression enabled the determination of the mUltiplicity of infection 
and time of harvest for the recombinant protein. Two six-well plates were seeded with 1 06 
SF9 cells. One well in each plate had an uninfected control and was harvested 24-48 hours 
after the other wells had been infected. This control was processed and run alongside the 
time point samples, providing information on background cellular protein levels. Plate 1 was 
infected with an MOl of 5 and plate 2 was infected with · an MOl of 1 0. The plates were 
incubated at 27°C. Time points were taken at 24 hour intervals to determine the point 'of 
optimal expression of the lung carboxyl esterase. Once a time point of optimal protein 
expression had been determined, a second time course with intermediate time points was 
performed to further optimize the protein expression levels. Cells were harvested at indicated 
time points. Cells were pelleted by centrifugation at 800 X g for 1 0  minutes at 4°C to prevent 
proteolysis. The cell pellets and the supernatants were stored at -70°C. 
Processing time point samples 
Lysis buffer ( 1 00 Ill) containing 0. 1 % Triton X- I 00 in PBS and appropriate protease 
inhibitors (pMSF: 1 00 Ilg/ml, Leupeptin :  0 .5  Ilg/ml and Aprotinin: 0 . 5  Ilg/ml) was added to 
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each 1 06 cells from the pellets described above. The cells were vortexed to break up the cell 
pellet to begin lysis and the samples were incubated on ice for 30-45 minutes and vortexed 
every 1 0  minutes to assist lysis. Once lysis was complete, cellular debris was centrifuged at 
1 000 X g for 1 0  minutes at 4°C. Efficiency of cell lysis was be checked by adding 1 J..l1 of 
trypan blue to 1 0  J..l1 of sample and observed on a hemocytometer. All cells stained blue when 
lysis was complete. Recombinant protein was identified using SDS-PAGE and Northern blot 
analysis. 
Large-scale expression of recombinant protein 
Once protein expression had been optimized, large-scale expression of the protein was 
performed. A large-scale, high titer stock ofthe lung carboxylesterase recombinant virus was 
generated in order to infect many large-scale cultures and ensure consistency in protein 
expression. Spinner flasks (250 ml) were used initially and seeded at 1 X 1 06 cells/ml with 
SF9 cells. Cell viability was maintained at >95%. These cell cultures were up-scaled to I 
liter when the density reached 2 . 5  X 1 06 cells/ml. The 1 liter suspension was infected with 
5 ml of the high titer stock of the lung carboxylesterase recombinant virus, and monitored 
daily. 
Column purification of recombinant protein 
The histidine fusion tag was used to purify the lung carboxylesterase recombinant 
protein with a nickel-chelating resin (Initrogen, Carlsbad, CA). The column was centrifuged 
at 800 X g in a swinging bucket rotor for 2 minutes to pack the resin. The top of the column 
was removed, the buffer was aspirated and 7 mJ of sterile water was added. The top of the 
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column was replaced and the column was centrifuged at 800 X g for 2 minutes. The water 
was aspirated and the water wash was repeated. The water was aspirated and 7 ml of native 
binding buffer (20 mM sodium phosphate and 500 mM sodium chloride, pH 7 .8)  was added 
to the column. Resin was resuspended by gentle shaking for 2 minutes and then centrifuged 
for 2 minutes at 800 X g. The native binding buffer was aspirated and this wash step was 
repeated 2X. An aliquot of the large-scale infection (SO ml) was removed and centrifuged at 
2000 rpm for 1 0  minutes. The cell pellet was resuspended in 1 0  ml of native binding buffer 
containing leupeptin at a concentration of 0 . 5  /lg/ml. The cell suspension was sonicated at 
30 % duty cycle, setting 3 for 30  seconds (X 2) on the Heat Systems Ultrasonic Processor, 
and the DNA was sheared by passing the preparation through an 1 8  gauge needle 4 times. 
The cell debris was removed by centrifugation at 1 0,000 X g for 30 minutes at 4°C. An 
aliquot of the preparation (5 ml) was added to the pre-equilibrated column and resuspended 
by gentle shaking for 2 minutes. The column was centrifuged at 800 X g for 2 minutes. The 
supernatant fluid was removed and stored and the second 5 ml aliquot was added to the 
column. The column was resuspended by shaking for 2 minutes and centrifuged for 2 minutes 
at 800 X g. The lysate was removed and stored. The column was washed twice with 4 m! 
of native binding buffer, resuspended by gentle shaking for 2 minutes and centrifuged at 800 
X g for 2 minutes. The column was washed with 4 ml of native wash buffer (20 mM sodium 
phosphate and 500 mM sodium chloride, pH 6.0), resuspended for 2 minutes by gentle 
shaking and centrifuged for 2 minutes at 800 X g. The column was clamped in a vertical 
position and the cap at the lower end was removed . The protein was eluted by the 
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consecutive application of 5 ml of each of the three imidazole elution buffers ( 25, 50 or 200 
mM imidazole, 20 mM sodium phosphate and 500 mM sodium chloride, pH 6.0). Fractions 
(I ml) were collected and the 00280 for each was determined. 
Site-directed mutagenesis 
The six amino acid residue differences between the rat lung carboxyl esterase and the 
hepatic cholesterol ester hydrolase were mutated one by one in a cumulative fashion with each 
successive mutation containing all of the previous mutations. Four transition point mutations 
and two transversion point mutations were made in the lung carboxyl esterase cONA. The 
order of the point mutations and their corresponding amino acid changes were as follows: 
Mutation I :  nucleotide 557, A to G, GIn to Arg; Mutation 2: nucleotide 1 3 3 1 ,  C to T, Thr 
to Met; Mutation 3 :  nucleotide 1 474, A to C, Lys to GIn; Mutation 4: nucleotide 1 472, G 
to C, Ser to Thr; Mutation 5 :  nucleotide 1 269, G to A, Met to lie; Mutation 6 :  nucleotide 
1 5 1 7, A to G, Asn to Sec Mutation 6 was not carried out. The wild-type hepatic CEH 
previously cloned into the pCR TM3 vector was used as a representative example of the sixth 
and final mutation. The QuickChange™ site-directed mutagenesis kit from Stratagene (La 
Jolla, CA) was according to the manufacturer's instructions. All primers were greater than 
35 base pairs in length and each of their melting temperatures were above 78° C. The formula 
used to calculate the melting temperatures was T m = 8 1 . 5 + OA I (%GC) - 6751N - % 
mismatch where N is the primer length in base pairs. The primers used in each reaction were 
as follows (the bold nucleotide represents that which was mutated): 
SDM 557 
l4IGGG GAT GAA CAC AGC CGG GGC AAC TGG GGT CAC TIG GS77 
SDM 1 33 1 
13 1 1GCT GGA GCC CCC ACC TIC ATG TAT GAA TIT GAG TAT CGC cml 
SDM 1 474 
1 4SSG GAG ACC AA T CTC AGC CAA ATG GTG ATG AAA T AC TGG GCCI497 
SDM 1 472 
1 448CC TCA GAA GAG ACC AAT CTC ACC CAA ATG GTG ATG AAA T AC TGG GCI496 
SDM 1 269 
1148GGA CTI GGT TGC AGA TGT GAT A TI TGG TGT CCC ATC AGT AAT GG1191 
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The l OX reaction buffer (5 �1)( 1 00 rnM KCI, 1 00 rnM (NH4)2S04, 200 rnM Tris-HCI (pH 
8 . 8), 20 rnM MgS04, 1% Triton X- I OO and I mglml nuclease-free bovine serum albumin) 
was combined with 30 ng of the plasmid DNA, 1 25 ng of each of the sense and antisense 
primers, I �I of the dNTP mix and double-distilled water was added to a final volume of 50 
�1 .  2.5 units ofPfuTurbo DNA polymerase was added and the reaction was overlaid with 30 
�I of mineral oil .  The cycling parameters were as follows: I cycle at 95°C for 30 seconds, 12 
cycles at 95°C for 30  seconds, 55°C for I minute and 68°C for 14 minutes. After cycling the 
reactions were placed on ice for 2 minutes. The Dpn I restriction enzyme (I 0 units) was then 
added, the reactions were mixed thoroughly, microcentrifuged for I minute and then 
incubated for I hour at 3 7°C. The epicurian Coli XL I -Blue supercompetent cells (50 �I) 
were thawed on ice in pre-chilled Falcon 2059 polypropylene tubes. The Dpn I treated 
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reactions ( I  Ill) was added to the cells, mixed gently and incubated on ice for 30  minutes. 
Each of the transformation reactions was heat pulsed for 45 seconds at 42°C and then placed 
on ice for 2 minutes. NZY+ broth (500 Ill, preheated to 42°C) was added to the 
transformation reactions and the reactions were incubated for 1 hour at 3 7°C with shaking at 
23 5 rpm. The entire volume of the reaction was then plated on LB/ampicillin agar plates and 
incubated at 37°C for 1 6  hours. 
Confirmation of the mutated lung carboxylesterase sequence 
Colonies were selected and plasmid DNA was prepared using an alkaline lysis method. 
The plasmid DNA was ethanol precipitated and resuspended in 20 III of autoclaved water. 
This plasmid preparation ( 1  Ill) was used to sequence the mutant daughter plasmid with each 
of the sequencing primers designed from the lung carboxyl esterase sequence and separated 
about 250 bp apart : 
Sense primers 
XHO: l'CCG CTC GAG CTG TGG GCT A TT TGT TCC TTC CAC3' 
SP I :  5'TTC ACC AAC AGG AAG GA3' 
SP2: l'TTC AGC ACA GGG GAT GA3' 
SP3 : l'CAA ACT GGA CTT ACT TG3' 
SP4 :  5'GGA CTT GGT TGA AGA TG3' 
SP5 :  5'AGG GTA CCT GAA GAT TGG TG3' 
Antisense primers 
XBA: YGCT CTA GAA GCA ATA AGG TIA AGT ATI TIC CCl' 
ASP 1 :  5'CCA GTG GGA TGG TIC CTC TGl' 
ASP2: YGTI CAT CAC CAT GGT CTC CGl' 
ASP3 : 5'TCA GAG A TI TIC AGT GTI GGl' 
ASP4: YCCA GGA GTI CAT CCT CTG TCl' 
ASPS :  YCCA AAG TIG GCA ATG TIG TCl' 
ASP6: YCAG GTA GAG GCA GTC TIC AGl' 
ASP8:  5'TAC CCC CAA GCT GTG CAC GCA GCA AGl' 
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This confirmed the presence of the desired mutation and ensured that no spurious mutations 
were made that would interfere with the translation of the mutated protein ,  Each mutant 
plasmid was sequenced in both the forward and reverse dir.ections using the ABI PRISM� 
Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA), 
Reaction mixtures (20111) was made with 450 ng of the eukaryotic expression vector pCRJ 
containing the mutated lung carboxyl esterase sequence, 8 ,0  III of the terminator ready 
reaction mix (A-Dye Terminator, C-Dye Terminator, G-Dye Terminator, T -Dye Terminator, 
dITP, dATP, dCTP, dTTP, Tris-HCL pH 9 ,0, MgCI2, thermal stable pyrophosphatase, and 
AmpliTaq DNA Polymerase, FS), and 3 , 2  pmoles of either sense or antisense primers, Each 
reaction mixture was overlaid with one drop of mineral oil . The cycle sequencing profile 
consisted of denaturation at 96°C for 1 5  seconds, primer annealing at 50°C for 7 seconds, and 
extension at 60°C for 4 minutes repeated for 25 cycles, Centri-Sep spin columns (princeton 
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Separations, Inc., Adelphia, NJ) were used to remove excess DyeDeoxyTM terminators from 
the completed DNA sequencing reactions. The reactions were analyzed on the Applied 
Biosystems DNA Sequencer 373A. 
Transfection of the mutated lung carboxylesterase cDNAs 
The Medical College of Virginia, Virginia Commonwealth University Molecular 
Biology Core facility purified each of the mutated plasmids using a double banded cesium 
chloride gradient. Cos-7 cells were seeded to 90% confluency in 60 mm transfection plates. 
4 J..lg of the mutant plasmid DNA was incubated with 1 2J..l1 of Lipofectamine (GibcoBRL, 
Gaithersburg, MD) in a 3 :  I ratio of Lipofectamine:plasmid DNA in 1 . 5 ml of serum-free 
medium. The mixture was incubated for 30 minutes at room temperature to allow for proper 
formation of the positively charged liposomal complexes. An additional 1 . 5 ml of serum-free 
medium was added to the mixture after incubation and the J.O rnl liposomal complex solution 
was overlaid onto the monolayer of Cos-7 cells and incubated at 3 7"C in a humidified 
incubator with 5 . 0% CO2 for 24 hours. After 24 hours, 2 rnl of complete DMEM medium 
with 20% fetal bovine serum was added to the 60 mm culture dishes and the incubation 
continued for an additional 24 hours. After a total of 48 hours of incubation, the cells were 
harvested in I ml of 250 mM phosphate buffer, pH 7 .4 containing 250 mM sucrose and 
protease inhibitors, 2mM 3-methyl propionate, 0 .5  mM benzoyl arginine and 5 mM 
benzamidine. The cell suspension was sonicated using Heat Systems Ultrasonic Processor, 
and the cell debris was removed by centrifugation at 1 0,000 X g for 30 minutes at 4°C. The 
post-mitochondrial supernatant was assayed for activity towards p-nitrophenyl acetate, p-




Protein was estimated by BioRad (Hercules, CA) dye binding assay according to 
the manufacturer ' s  instructions using bovine serum albumin as standard . 
Spectrophotometric enzyme assays 
To measure activity towards p-nitrophenyl acetate and p-nitrophenyl caprylate (Sigma 
Chemical Co. ,  St. Louis, MO), an aliquot of sample protein was diluted with 200 mM 
phosphate buffer, S mM p-mercaptoethanol and 80 mM potassium chloride, in a final volume 
of 1 m! . The reaction was started by the addition of p-nitrophenyl acetate or p-nitrophenyl 
caprylate to a final concentration of 0.2 mM and incubated at 3 7°C for 5 minutes for p� 
nitro phenyl acetate or 1 5  minutes for p-nitrophenyl caprylate. The release of p-nitrophenol 
was monitored at 400 nm. 
Radiometric enzyme assay 
The radiometric assay used was described by Ghosh and Grogan for the substrate 
cholesteryl oleate (Ghosh and Grogan, 1 989). An aliquot of the sample (5 Ilg to 20 Ilg 
protein) was added to the assay buffer and the reaction was started by the addition of 75 11M 
cholesteryl [ 1 _14C] oleate (New England Nuclear, Boston, MA) with specific radioactivity of 
1 2,000- 1 3 ,000 dpmlnmole. The reaction mixture was incubated for 30  minutes at 3 7°C and 
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then stopped by the addition of 3 .25 ml of methanol :choroform:hexane (3 . 85 : 3 .42 :2 .73 ;  
v/v/v) and SO III  of 1M NaOH. The tubes were vortexed and phases separated by 
centrifugation. A 1 ml aliquot of the aqueous phase was transferred to a scintillation vial and 
the associated radioactivity was determined. 
Determination of pH optima 
pH optima were determined for the activity of the recombinantly purified lung 
carboxylesterase. The purified carboxyl esterase (7 Ilg) was diluted with 200 mM phosphate 
buffer, S mM p-mercaptoethanol and 80 mM potassium chloride at pH 4 .0, 5 .0, 6.0, 7.4, 8 .0 
or 9 .0 ,  in a final volume of 1 ml The reaction was started by the addition of p-nitrophenyl 
acetate or p-nitrophenyl caprylate to a final concentration of 0 .2  mM and incubated at 37°C 
for 5 minutes for acetate and for I S  minutes for caprylate. The release of p-nitrophenol was 
monitored at 400 nm. The data was graphed as specific activity (nmoles/hr/llg) vs. pH. 
Enzyme kinetics 
V max and KM were determined for the recombinantIy purified lung carboxylesterase 
using standard Michaelis-Menton techniques. The purified carboxylesterase (7 Ilg) was 
diluted with 200 mM phosphate buffer, 5 mM p-mercaptoethanol and 80 mM potassium 
chloride, in a final volume of 1 ml The reaction was started by the addition ofp-nitrophenyl 
acetate or p-nitrophenyl caprylate to a final concentration of 0.05 mM, 0. 1 mM, 0 .2 mM, 0.4 
mM or 0.8 mM and incubated at 37°C for 5 minutes for acetate and for 1 5 minutes for 
caprylate. The release of p-nitrophenol was monitored at 400 nm. Data was graphed as I Iv 
vs. I /s. Kcac was determined numerically based on the calculated values of V max and KM. 
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Results 
Cloning the rat lung carboxylesterase cDNA 
RT PCR was used to amplify the cDNA of rat lung carboxyl esterase from total rat 
lung RNA. The cDNA was amplified and ligated into the TA cloning vector pCR3 . 
Digestion of the plasmid DNA with EcoR 1 showed that this clone contained an insert of 
approximately 2kb . The cDNA sequence and predicted amino acid sequence obtained from 
this clone are shown in Figure 2. The first ATG codon, 1 1 bp from the 5' terminus, was 
identified as the start codon by the sequence CCACAA TG, differing only in the fifth 
nucleotide from the consensus sequence, CCACCATG, described by Minchiotti et al 
(Minchiotti et ai, 1 99 1 ) . The nucleotide sequence surrounding this ATG codon also ­
corresponds to the optimal consensus sequence AXXATGXG, for the initiation of translation, 
by eukaryotic ribosomes, as described by Kozak (Kozak, 1 986). Beginning with the 
consensus initiation codon, there exists a long open reading frame coding for 565 amino acids. 
A termination codon, TGA, is present at 1 696 bp, leaving a 1 43 bp 3 '-untranslated region. 
The predicted molecular weight of the nonglycosylated protein is 62 1 1 7, and there are two 
potential N-glycosylation sites at Asn79 and Asn489 . 
Verification of the lung carboxylesterase 
As shown in Figure 3, two full length clones were obtained by RT PCR and sequenced 
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Figure 2: The cDNA nucleotide sequence and the deduced amino acid sequence of the rat 
lung carboxylesterase. The first nucleotide of the full-length cDNA and the methionine 
residue translating the start codon are numbered as I .  The conserved active site motif 
(GXSXG) is shown in bold face and underlined. * indicates potential N-glycosylation sites. 
The nineteen amino acids corresponding to the lung carboxyl esterase previously purified. 
(Gaustad et ai, 1 99 1 )  are underlined. 
. 
- 1 0 TCCTTCCACA - 1 
ATC eGC CTC T AC CCT CTG GTC TGC CTT T"M' CTT GCT GeG TGC ACA GCT TGC GGG T AC CCA TCC TCA CCA 69 
1 Met Arg Leu Tyr Pro Leu Val Trp Leu Phe Leu AI", Ala ey. Thr Ala Trp Gly Tyr Pro Ser Ser Pro 23 
'70 CCT GTC GTG MC ACT GTI AM GGC AM GTC CTG GGG AJ',I,{; TAT GTC MT TIC GM eGA T"M' GCA CAG ccr 1 3 8  
24 P r o  v ", l  Val Asn Thr V a l  Lys Gly Lye V",} Leu G ly Lys Tyr Val Asn Leu G l u  Gly phe Ala G I n  Pro 4 6  
D9 GTC G CT  GTT TIC CTG GGA ATC CCC TI C  GCC AJ',I,{; CCC CCT CTT GeC TCC TTC PGG T"M' G CT  CCA CCA CAG 207  
4 '7 V a l  Ala Val p h e  Leu G l y  I Ie P r o  P h e  A l a  Lys P r o  P r o  Leu G l y  S e r  L e u  Arg p h e  Ala P r o  P r o  G I n  69 
208 CCT GCA G AG  CCT TGG M C  T"M' GTC AJ',I,{; MT A CT  ACC TCC TAC CCA C CT  ATC TGC T CT  C M  GAT G CT  GTT 216 
10 P r o  A l a  G l u  Pro Trp A s n  Phe Val L y s  A s n  T h r  T h r  S e r  Tyr P r o  Pro Met ey. S e r  G I n  A s p  Al a V a l  92 
277 GeA GGG CN:; GTT CTC TCA GAG err TTC ACC MC N:;G AJ',I,{; GM MC ATT CCT TTA CAG T"M' TCT GM GAC 345  
93 G l y  G l y  G I n  v a l  Leu S e r  G l u  Leu p h e  T h r  Asn Arg Lys G l u  Asn l I e  P r o  Leu G I n  P h e  S e r  G i u  ASp 1 1 5  
3 4 6  TCC CT C  T AC C1'G MC G TT  TAT ACT CCC GCT GAC TIC ACA AJ',I,{; MC PCC eGG CT A CCA GTC ATG GTC TCG 4 1 4 
1 1 6  ey. Leu Tyr Leu Asn Va I Tyr Thr Pro Al a Asp Leu Thr Lys Asn Ser Arg Leu Pro Va I Met Va I Trp 1 3 8  
4 1 5  ATC CAT GGA GeT GGA CTG GTA GTC GGT GGA GCA TCC ACC TAT GAT GGA CAG GTT CT C  T CT  GCC CAT GM 4 8 3  
D9 I l e  H i s  G l y  G l y  G l y  Leu V a l  V a l  G l y  G l y  A l a  S e r  Thr Tyr Asp Gly G I n  V a l  Leu S e r  A l a  H i s  G l u  1 6 1  
4 8 4  MT GTC GTC GTG GTC ACC ATT CAG TAT eGC CT'T GGC ATC TGC GGA TTC TT C  AG C  ACA GGG GAT GM CAC 552 
1 6 2  A s n  Val Val Val v ", l  Thr I l e  G I n  Tyl' Arg L e u  G l y  I l e  T r p  G l y  P h e  P h e  Sel' Thr G l y  A S p  G l u  H i s  1 8 4  
5 5 3  AGC CAG GGC M C  TGG GGT CAC TIC GAC CAG GTC G CT  GCA CT A CAC TeG GTC CAG GAC MC ATT GCC MC 62 1 
1 8 5  Ser G I n  G l y  Asn Trp G l y  H i s  Leu ASp G I n  Val Ala Ala Leu H i s  Trp Val G I n  Asp Asn I l e Ala Asn 207  
622 TTT GGG GGT M C  CCA GGC T CT  GTG ACC ATC TTT eGA G M  T CT  GCA GGA GGT TIC NJ T  GTC Tcr G CT  CTT 690 
208 P h e  Gly G l y  A s n  Pro G l y  Sel' val T h l'  I l e  p h e  oly Olu S.r Ah oly G l y  p h e  Ser V a l  Sel' A l a  Leu 230 
6 9 1  GTG ITA TCT C CT  CT G  G C C  AJ',I,{; M C  CTC ITC CAC N:;G GCC AIT T CT  G N:;  N:; T  GGT GTC GTC CTC ACT T CT  759 
2 3 1  Val L e u  S e r  Pro L e u  A l a  L y e  A s n  L e u  P h e  H i s  Arg A l a  l I e  S e r  G l u  S e r  G l y  Val Val L e u  T h r  Ser 253 
160 GCT CT G  ATI ACA ACA GAT NJ C  AJ',I,{; CCC AT'T G CT  MT CT G  A TT  GCT A CT  CTT T CT  GGG TCT AAA ACC ACC 828  
254 Ala L e u  l I e Thl' T h r  ASp S e l'  Lye P r o  l I e  Ala Asn Leu l I e  Ala Thl' Leu S e r  G l y  eye Lys T h r  Thl' 2'76  
829 ACA TCA GCT GTI ATG G TT  CAT TGC CT G  CGC CAG AJ',I,{; ACA GAe GAT G M  CT C  CTG G N;  AC'r TCA TI A  AM 897 
277  Thl' Sel' A l a  Val Met Val H i s  ey. Leu Arg G I n  Lys T h r  G l u  Asp G l u  Leu Leu G l u  T h r  S e r  L e u  Lys 299 
8 98  TIG AAT CTT TIC AA A  CT G  GAC TT A  CT'T GGA M C  CCA A AA  G N;  N;C TAT CCC TI C  CT A  C CT  A CT  GTC ATI 966 
300 Leu Asn Leu phe Lys Leu ASp Leu Leu G l y  Asn Pro Lys G l u  Ser Tyr Pro Phe Leu Pro Thr Val l I e 322 
967  GAC GGA GTC GTG CT G  CCA AJ1G ACA CCA G M  GN:; ATC CTG G CT  e N:;  AJ1G � T  TIC M C  ACA GTC CCC TAC 1 035 
323 A S p  G l y  Val Val L e u  Pro L y e  T h r  P r o  e l u  C l u  I l e  L e u  A l a  G l u  Lys S e r  Phe A e n  T h r  v a l  Pro Tyr 345  
1 036 ATA GTe GGC ATC M e  AJ',I,{; C M  G N:;  TTT eGC TGG ATC ATI CCA ACG CTT ATe GeC TAT CCA erc TCC GAA 1 1 04 
346  l I e  Val C l y  l I e  A s n  L y s  C i n  C l u  p h e  G l y  T r p  l I e  l I e P r o  Thr L e u  M e t  C l y  T y r  P r o  L e u  Ser G l u  368 
1 1 05 GGC AAA CTG GAC C N:;  AAA ACA GCC AAA TCC erc TIC TGC AJ1G TCC T A C  CCA ACA CTG AAA ATC T CT  GN:; 1 1 73 
369  Gly Lye Leu ASp G I n  Lys Thr Ala Lys Ser Leu Leu Trp Lys Ser Tyr Pro Thr Leu Lye I 1 e  Ser C l u  3 9 1  
1 1 74 AAA ATC ATI CCA GTG CTI ecc G N:;  AJ1G T AC TI C  GGA GGG ACA CAT GAC C CT  GCC AAA N:;G AAA CAC CTG 1 242  
392 Lye M e t  l I e P r o  V a l  v a l  Ala G l u  Lys Tyr P h e  G l y  C l y  T h r  ASp Asp P r o  Ala Lye Arg Lys Aep Leu 4 1 4  
1 2 4 3  TIC CAG GAe TTC GTT GCA GAT GTC ATG TTT GGT GTC CCA TCA GTA ATe GTC T CT  eGA N:;T CAC N:;A GAT 1 3 1 1  
4 1 5  phe e l n  Asp Leu Val Ala ASp Val Met phe e l y  Val Pro Ser Val Met Val Ser Arg Ser H i e  Arg Asp 4 3 7  
1 3 1 2 GCT GGA GCC CCC ACC TIC ACG TAT G M  TTT G N:;  TAT CGC CCA AGC TTT GT A TCA GCC ATe N; G  CCC AJ1G 1 380 
4 3 8  A l a  G l y  Al a P r o  T h r  P h e  T h r  T y r  G l u  p h e  G l u  T y r  Arg P r o  S e r  P h e  Val Ser Ala M e t  A r g  P r o  Lys 460  
D 8 1  ACA GTG ATC GGA GAC CAT GGT GAT G M  erc TIC TCA GTA TTT GGA TCT CCA TTT TI A  AM GAT GGT GCC 1 4 4 9  
4 6 1  Thr Val I l e  G l y  Aep H i e  G l y  Aep G l u  Leu Phe Ser Val phe e l y  Ser Pro Phe Leu Lye Aep G l y  A l a  4 83 
1 4 5 0  TCA GM GN:; GN:; ACC MT C'rC AGC AAA ATe GTC ATC AM TAC TeG GCC MC T'TT GCT eGG MT GGG MC 1 5 1 8  
4 8 4  Ser G l u  G l u  G l u  Thr Asn Leu Ser Lye Met Val Met Lye Tyr Trp Al a Aen Phe Al a Arg Asn G l y  Asn 506 
1 5 1  9 CCT AAT GGG GGA GGG CTG CCC CAT TGG CCA GM TAT GAC CN:; AN:; GM GGG T AC CTG AJ1G ATT GGT GCC 1 5 81  
507 P r o  Asn G l y  Gly G l y  Leu P r o  H i s  T r p  P r o  C l u  Tyr ASp C l n  Lys G l u  G l y  Tyr Leu Lye I l e  G l y  A l a  529 
1 58 8  TCA ACT C At:;  GCA G C C  C N:;  N:;G CTG A J1G  GAC AAA G M  GTG G CT  T"M' TeG T CT  GAt:; C'rC N; G  GCC A At:;  GAt:; 1656 
530 S e r  T h r  G I n  Ala Al a G l n  Arg Leu Lye Asp Lye G l u  v a l  A l a  P h e  T r p  S e r  G l u  Leu Arg A l a  Lye G l u  552 
1 6 5 1  GCA GCA GN:; GAA CCA TCC CAC TGC AAA CAT G TI  C N:;  erc TCATCAGCAGGGTCN:;CCATGTITCN:;AACCTGGN:;CTA 1 134 
553 Ala A l a  G l u  G i u  Pro S e r  H i s  T r p  Lye H i s  val G l u  Leu 565 
1 135 AAGGGGMTT ATICCACN:;AJ1GATTI'1'GT AAN;ACAT MCAC'ITCTTGTCTrTGAGACT AT AACATCACATGGT ATTI'1'GT ACAAATCCAT 1 8)  5 
1 836 TAAA 
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Figure 3 :  The cloning strategy used to determine the cDNA sequence of the rat lung 
carboxylesterase. 3 1lg of RNA was used in the first strand synthesis which was carried out 
using the Superscript™ Preamplification System (GibcoBRL). The 5' RACE System for 
Rapid Amplification of cDNA Ends (GibcoBRL) was used according to the manufacturer's 
instructions in order to obtain a 1 000 bp 5' RACE clone. Primer ASP3 was used with the 
anchor primer supplied by the !cit for amplification. The amplification profile consisted of 
denaturation at 94°C for 30 seconds, primer annealing at 49° C for 45 seconds and extension 
at nOc for 2 minutes. A 1 200 bp band was obtained, and a I IlI aliquot of this amplification 
product was reamplified using the nested universal amplification primer (UAP) supplied by 
the !cit and the nested antisense primer ASP4. The same amplification profile was repeated_ 
and a 1 000 bp band was obtained, cloned and sequenced as described above . Sense primer 
SP2 and antisense primer ASP 1 were used to amplify a 950 bp intermediate band by RT PCR 
which was subsequently cloned and sequenced as described above. Finally, sense primer SP2 
and antisense primer XBA were used to amplify a 1 300 bp band which was cloned and 
sequenced as described in materials and methods. Primers XHO and XBA produced two full 
length 1 839  bp clones. 
5 1  
1 .  XHO� .. XBA 
UAP� .. ASP4 
2. 
SP2 � .. XBA 
3. 
SP2 � .. ASP l 
4. 
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in the forward and reverse directions. In order to confirm this sequence, three additional 
clones were obtained, and each was sequenced in both the forward and reverse directions. 
This thorough cloning method eliminated the possibility of sequencing errors. The 
authenticity of the 1 839 bp lung carboxyl esterase was further verified by expression in Cos-7 
cells transfected with the pCR3 plasmid containing the full-length cDNA. Expression was 
driven by the CMV promoter located upstream of the 5' end of the cDNA. As shown in 
Figure 4, a 4-fold higher activity towards p-nitrophenyl acetate and a 5 . 5-fold higher activity 
towards p-nitrophenyl caprylate was present in extracts from cells transfected with the lung 
carboxylesterase cDNA as compared to mock transfected controls. 
Total RNA from rat lung was probed with the full-length lung carboxyl esterase cDNA 
on northern blots. As shown in Figure 5,  the probe hybridized in the lung RNA to a single 
2 . 5  kb band indicating the presence of the mRNA in the lung. 
Cellular localization of the lung carboxylesterase 
Localization of the rat lung carboxylesterase mRNA was determined using an in situ 
hybridization technique. Lung tissue sections were hybridized overnight with a biotin-labeled 
probe, complementary to the 5' PCR primer used to clone the full length lung 
carboxyl esterase cDNA. Specific hybridization of this biotinylated probe was detected using 
rhodamine conjugated streptavidin. Affinity labeling was visualized using the Meridian 
Instruments OPTIMA scanning confocal fluorescence microscope with 5 1 6 nm laser 
excitation and dual wavelength detection of emission. As indicated in Figure 6, the message 
is located in the epithelial lining of the small diameter airway at the terminal bronchiole level 
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Figure 4 :  Lung carboxyl esterase activity in transfected Cos-7 cells. 2 Ilg of plasmid DNA 
encoding the lung carboxyl esterase were incubated with 6 III of lipofectamine in 750 III of 
serum-free medium for 30 minutes at room temperature to allow proper formation of the 
cationic liposomal complexes. The cells were washed once with serum-free medium. 750 III 
of serum-free medium was added to the plasmid DNAILipofectamine mixture, and the 1 . 5 mI 
solution was overlaid on the cells. After a total of 48 hours of incubation, the cells were 
harvested in I ml of 250 mM phosphate buffer, pH 7 .4 containing 250 mM sucrose and 
protease inhibitors, 2mM 3 -methyl propionate, 0 . 5  mM benzoyl arginine and 5 mM 
benzamidine. The cell suspension was sonicated using Heat Systems Ultrasonic Processor, _ 
and the cell debris was removed by centrifugation at 1 0,000 X g for 30 minutes at 4°C. The 
post- mitochondrial supernatant was assayed for carboxyl esterase activity. Panel A shows . 
activity towards p-nitrophenyl acetate and panel B shows activity towards p-nitrophenyl 
caprylate. The cells were transfected with lipofectamine alone (Control) or with lipofectamine 
and pCR-3 containing the carboxyl esterase eDNA (Exp. 1 and Exp. 2) .  Cells were harvested 
and Iysates assayed for Carboxyl esterase activity. Activity is expressed as nmoles para­
nitrophenol released/h. 
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Figure 5 :  Northern blot analysis o f  rat lung RNA probed with lung carboxylesterase cDNA. 
Total RNA ( J  OJlg) from rat lung was electrophoresed on an agarose gel, transferred to 
membrane, hybridized to the radiolabled full-length cDNA probe and developed by 
autoradiography. The 28S and 1 8S RNA bands were visualized by ethidium bromide staining 






Figure 6 :  In Situ hybridization in rat lung tissue sections. A 1 0  /lm sample section (panel 3 )  
was hybridized overnight with biotin-labeled probe complimentary t o  the 5' peR primer used 
to clone the rat lung carboxylesterase. The section was then incubated with rhodamine 
conjugated to streptavidin. Affinity labeling was imaged using the Meridian Instruments 
OPTIMA scanning confocal fluorescence microscope with 5 1 6  nm laser excitation and dual 
wavelength detection of emission. A 1 0  /lm serial control sample (Panel 2) was treate� 
identically to the sample section, except for hybridization with probe. A 1 0  /lm serial section 
was stained with hemotoxylin and eosin (panel I )  and the boxed area represents the arefl 
shown in Panels 2 and 3 .  
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Also shown in Figure 6 is a serial lung section stained with hemotoxylin and eosin to more 
clearly define the structure of the epithelial lining of the small diameter airway at the terminal 
bronchiole level. The localization of the pulmonary carboxyl esterase mRNA may be further 
confirmed by the use of a biotinylated sense/mis-sense oligonucleotide in control 
hybridizations. Alternatively, RNase treated tissue sections may be used to control for 
nonspecific binding of the biotinylated oligonucleotide probes. 
Organophosphorus inhibition of the lung carboxylesterase 
The inhibitory effect of the organophosphorus compound paraoxon toward the lung 
carboxylesterase was also determined. 0 1 11M, 1 .0 !lM and 1 0  11M paraoxon was incubated 
with the transfected lung carboxylesterase for 1 5  min. and 30 min . and the reaction was 
started by the addition ofp-nitrophenyl caprylate. The activity of the transfected protein was 
assayed as described above. 0 . 1 11M paraoxon inhibited 93% of the transfected 
carboxylesterase activity after incubation with 40 Ilg of the protein for 1 5  minutes (Figure 7). 
After a 30 minute incubation with 40 Ilg of the transfected carboxylesterase, 0. 1 11M 
paraoxon inhibited 1 00% of the transfected carboxyl esterase activity (Figure 7). 
Homologous recombination and purification of recombinant products 
The 1 839 bp lung carboxylesterase cDNA was cut from the eukaryotic expression 
vector peR3 with EcoR I and re-ligated into the multiple cloning site of the baculovirus 
transfer vector pBlueBacHis2B containing a 5' histidine tag. The orientation of the insert was 
confirmed using restriction analysis. Further confirmation of the insert orientation was 
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Figure 7: Paraoxon inhibition of rat lung carboxylesterase. The full length lung 
carboxylesterase cDNA was transfected into Cos-7 cells. Expressd protein (35 Ilg-45 Ilg) 
was incubated with 0. 1 11M paraoxon for 1 5  minutes and 30 minutes. The inhibitory effect of 
the paraoxon towards the activity (nmoles/hr) of the transfected lung carboxylesterase was 
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obtained by sequencing the plasmid using both a 5' and 3' vector specific primer. Figure 8 
shows the sequence obtained. As indicated in bold, the start codon A TG is in the proper 
orientation at the 5' end of the plasmid. The transfer vector containing the lung 
carboxyl esterase cD N A was cotransfected with Bac-N -Blue viral DN A ( Invitrogen, Carlsbad, 
CA) into SF9 cells and homologously recombined to form the recombinant virus containing 
the rat lung carboxyl esterase cDNA. The recombinant products were purified by plaque 
assay. The transfer vector pBlueBacHis2B contains sequences homologous to the lacZ gene 
and ORF I 629 sequences in Bac-N-Blue linear DNA which produced blue recombinant 
plaques. PCR was used to establish the presence of the lung carboxylesterase insert in the 
putative recombinant virus and to confirm the isolation of pure, recombinant plaques. Figure 
9, lane 2 shows the expected 2 .2 kb band indicating a successful homologous recombination 
between the transfer vector and the viral DNA as well as the successful purification of the 
recombinant viral stock. 
Preparation of high titer viral stocks 
Two flasks were seeded with 2 X 1 06 log-phase SF9 cells to which 20 III of the viral 
stock was added and incubated at 27°C until 80-90% of the cells lysed. Figure 1 0  shows the 
time-dependant infection of the SF9 cells by the viral stock. Panel I shows uninfected healthy 
SF9 cells. Panel 2 which represents 1 2  hours post infection, shows nuclear swelling of the 
cells as a result of the cells being reprogrammed for viral replication, cytoskeletal 
rearrangements and host chromatin dispersing in the nucleus. 24 hours post infection is 
represented by increased nuclear swelling and viral budding caused by extensive viral 
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Figure 8: Confinnation of cloning of lung carboxyl esterase insert into pBluBacHis2B. 
Vector-specific forward and reverse sequencing primers were used to sequence the 5' and 3 '  
regions of the plasmid containing the insert. Insert was cloned into the vector multiple 
cloning region using EcoRI. The vector specific transcription start site, polyhistidine region, 
and A TG start site are all intact. Insert is also in the correct reading frame allowing for­
proper translation of the recombinant product. 
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5'T AAA T AAGT A TTTT ACTGTT TTCGT AACAG TTTTGT AA T A AAAAACCT AT 
* * * * *  
Vector specific transcription start site 
ATG CCG CGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GeT AGC 
* * * *  * * * * * * * * * * * * * * * * * * * * * * * * *  
Vector specific start codon Polyhistidine Tag 
GGT GGA CAG CAA ATG GGT CGG GAT CTG T AC GAC GAT GAC GAT AAG 
CCG AGe TCG AGA TCT GeA GeT GGT ACC ATG GAA TTC GGC TTC CGC 
TGT GGG CTA TTT GTT CCT TCC ACA ATG. 3' 
* * * *  
In-frame lung carboxyl esterase start codon 
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Figure 9: PCR analysis of recombinant virus. PCR was used to determine the presence of 
the lung carboxyl esterase insert in the putative recombinant virus and to confirm the isolation 
of pure, recombinant plaques. Log-phase Sf9 cells were seeded at a density of 5 X 1 05 in a 
l 2-well microtiter plate and viral stocks were grown. A sample was centrifuged at 5000 rpm 
for three minutes to pellet the cell debris. The viral DNA was extracted using 
phenol :chloroform and precipitated using sodium acetate and ethanol. The DNA was 
resuspended in 1 0  III of sterile water. 5 III of the isolated viral DNA was used in a 50 III PCR 
reaction which was cycled in a thermo cycler using the following parameters: Initial 
denaturation, one cycle at 94°C for two minutes; thirty cycles of denaturation, 94°C for two­
minutes, annealing, 55°C for two minutes and extension, noc for three minutes; final 
extension, one cycle at noc for seven minutes. 20lll of the PCR reaction was analyzed on 
a 1 % agarose gel. Lane 1 is a marker. Lanes 2 and 3 are controls. Lane 5 is the positive 
signal from the amplification of a successful homologous recombination. 
1 2 3 4 5  
+- 2. 3  Kb, 
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Figure 10 The time-dependant infection of the SF9 cells by the viral stock. Two flasks were 
seeded with 2 X 1 06 log-phase SF9 cells and infected with 20 III of the viral stock and 
incubated at 27°C until 80-90% of the cells lysed. Panel I shows uninfected healthy SF9 cells. 
Panel 2 which represents 1 2  hours post infection, shows nuclear swelling of the cells as a 
result of the cells being reprogrammed for viral replication, cytoskeletal rearrangements and 
host chromatin dispersing in the nucleus. 24 hours post infection is represented by increased 
nuclear swelling and viral budding caused by extensive viral replication as indicated in panel 
3 .  Panel 4 which represents 3 6  hours post infection, shows continued viral budding as well 
as the production of viral occlusion bodies. 48 hours post infection the cells begin to lyse as 
fibrous material accumulates in the nucleus as indicated in panel 5. Lastly, in panel 6 which 
represents 72 hours post infection, the cells are no longer synthesizing proteins and continue 








replication as indicated in panel 3 .  Panel 4 of Figure 1 0, which represents 3 6  hours post 
infection, shows continued viral budding as well as the production of viral occlusion bodies. 
48 hours post infection the cells begin to lyse as fibrous material accumulates in the nucleus 
as indicated in panel S .  Lastly, in panel 6 which represents 72 hours post infection, the cells 
are no longer synthesizing proteins and continue to lyse until all the cel ls die and only cell 
debris remains. When 80-90% of the SF9 cells had lysed the culture was harvested and added 
to a 500 ml suspension of iog-phase SF9 cells seeded to a density of 1 . 8 X 1 06 cells/ml. The 
progress of the infection was monitored daily by withdrawing a sample and using the trypan 
blue exclusion assay to determine the extent of cell lysis. The culture was harvested when 
>90% of the cells had lysed. The titer of the 500 ml high titer stock was determined as 
follows: ( I /dilution) X number of plaques = pfulml. The titer was determined to be 1 .2 X 107 
pfu/ml. 
Time course expression of recombinant protein 
A time course of expression enabled the determination of the multiplicity of infection 
and time of harvest for the recombinant protein. Two six-well plates were seeded with 1 06 
SF9 cells. One well in each plate had an uninfected control and was harvested 24-48 hours 
after the other wells had been infected. This control was processed and run alongside the 
time point samples, providing information on background cellular protein levels. Plate 1 was 
infected with an MOl of 5 and plate 2 was infected with an MOl of 1 0. The volume of high 
titer stock used to infect the wells was determined as follows: Volume of Virus = (MOl 
desired)(Total number of Cells)( l iT iter of the viral stock). The plates were incubated at 
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27°C . Time points were taken at 24 hour intervals, and activity towards p-nitrophenyl 
caprylate was calculated to determine the point of optimal expression of the lung 
carboxylesterase. Highest carboxylesterase activity was seen after 96 hours, indicating 
optimal protein expression at this time. 
Large-scale expression and purification of recombinant protein 
Once protein expression had been optimized, large-scale expression of the protein was 
performed. Spinner flasks (250 ml) were seeded at 1 X 1 06 cells/ml with SF9 cells. Cell 
viability was maintained at >95%. These cell cultures were scaled up to 1 liter when the 
density reached 2 . 5  X 1 06 cells/mL The 1 liter suspension was infected with 5 ml of the high 
titer stock of the lung carboxylesterase recombinant virus, and harvested after 72 hours. The 
histidine fusion tag was used to purify the lung carboxyl esterase recombinant protein with a 
nickel-chelating resin. The 00280 was monitored as elution proceeded with increasing 
amounts ofimidizole from 25 mM to 50 mM to 200 mM. Figure I I  shows a maximum 00�80 
after elution with 25 mM imidizole, indicating that most of the protein was eluting at this 
point. This is supported by the coomassie stained SOS-PAGE gel in Figure 1 2, showing the 
products of elution from the Nickel-NT A column. Purification of the lung carboxyl esterase 
was achieved after elution from the column with 25 mM imidizole, as indicated by the band 
at 66 Kd in lane 3 of Figure 1 2. To further confirm these results another SOS-PAGE gel was 
run and silver stained, providing a more sensitive determination of protein purification. The 
band at 66 Kd in lane 3 of Figure 1 3 ,  indicates the lung carboxyl esterase was successfully 
purified after elution from the Nickel-NT A column with 25 mM imidizole. These data 
7 1  
Figure 11: Measurement of the 00280 of the nickel column elution of the recombinant lung 
carboxyl esterase. The 00280 was measured for each 1 mI fraction as elution proceeded with 
increasing amounts of irnidizole from 25 mM to 50 mM to 200 mM. There is a maximum 
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Figure 12 :  SDS-PAGE electrophoresis of recombinant lung carboxylesterase stained with 
Coomassie R-250.  A 1 0% SDS-PAGE gel was run at 50 mAmps for 3 hours, and stained 
overnight in I mg/mJ Coomasie R-250 in 50% methanol, 40% water and 1 0% acetic acid. 
Fractions 1 -5 of the 25 mM imidizole elution, fractions 1 -5 of the 50 mM imidizole elution 
and fraction 1 of the 200 mM imidizole elution are shown. 
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Figure 13 :  SDS-PAGE electrophoresis of recombinant lung carboxyl esterase stained with 
silver stain. A 1 0% SDS-PAGE gel was run at 50 mAmps for 3 hours, and stained with silver 
stain. Fractions 1 -5 of the 25 mM imidizole elution, fractions 1 -5 of the 50 mM imidizole 
elution and fraction I of the 200 mM imidizole elution are shown. 
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support the results of the OD280 measurements shown in Figure I I , which indicate that the 
most protein is eluted with 25 mM imidizole. 
Determination of specific activity of the purified protein 
The specific activities of the purified lung carboxyl esterase towards p-nitrophenyl 
acetate, p-nitrophenyl caprylate and cholesterol oleate were determined using aliquots from 
the first 25 mM imidizole eluted fraction (lane 3 in Figures I I  and 1 2).  The specific activity 
of the pure protein towards p-nitrophenyl acetate was 1 8 . 7  nmoles/hrhtg protein and towards 
p-nitrophenyl caprylate was 282.6 nmoles/hr/llg protein. The pure protein showed 
undetectable amounts of activity towards cholesterol oleate. 
Determination of enzymatic kinetic parameters of the purified protein 
V max and KM were determined for the purified recombinant lung carboxylesterase using 
standard Michaelis-Menton techniques. The protein amount remained constant as varying 
concentrations of substrates were used. The data was graphed as I lv vs. l is. Figures 1 4  and 
1 5  show the substrate concentration curves for the activity of the purified lung 
carboxylesterase towards p-nitrophenyl acetate and p-nitrophenyl caprylate, respectively. The 
calculated values for the V max, KM and Kca' for each substrate are shown in Table 4. 
Determination of pH optima for the purified protein 
pH optima were determined for the activity of the recombinantly purified lung 
carboxylesterase. 7 mg protein and 0 .2 mM substrate were used in each experiment as the 
pH of the assay buffer was changed from 4.0 to 9.0. Figures 1 6  and 1 7  show the pH optima 
for the activity of the purified protein towards p-nitrophenyl acetate and p-nitrophenyl 
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Figure 14 Lineweaver-Burk double reciprocal plot, l Iv vs. I /[S] . I /v is the rate of 
hydrolysis of p-nitrophenyl acetate by purified lung carboxylesterase. I /[S]  is the p­
nitrophenyl acetate concentration. 0 .05 mM, 0. 1 mM, 0.2 mM, 0.4 mM or 0 . 8  mM p­
nitrophenyl acetate was incubated at 3 7°C for 5 minutes with 7 1lg of the purified recombinant 
lung carboxylesterase. x-intercept is equal to - I IKM and y-intercept is equal to I /Ymax . 
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Figure 1 5  Lineweaver-Burk double reciprocal plot, I /v vs. I /[S] .  I /v is the rate of 
hydrolysis of p-nitrophenyl caprylate by purified lung carboxylesterase. I /[S]  is the p­
nitrophenyl caprylate concentration. 0.05 mM, 0. 1 mM, 0 .2 mM, 0.4 mM or 0 .8  mM p­
nitrophenyl caprylate was incubated at 3 7°C for 1 5  minutes with 7 IJ.g of the purified 
recombinant lung carboxylesterase. x-intercept is equal to - I IKM and y-intercept is equal to 
I /V max. 
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Table 4 :  Kinetic Determinations for Lung Carboxyl esterase Towards p-nitrophenyl Acetate 
d h I C I an p-rutroPI enyl aprylate 
Substrate KM (mM) V max (�olelhr/mg) Kcat (hr- l) 
p-nitrophenyl 2 286 67 
acetate 
p-nitrophenyl _ 045 1 9  4.4 
caprylate 
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Figure 16 pH Optima curve of the hydrolysis of p-nitrophenyl acetate by the purified 
recombinant lung carboxylesterase. The purified carboxylesterase (7 Ilg) was diluted with 
200 mM phosphate buffer, S mM p-mercaptoethanol and 80 mM potassium chloride at pH 
4.0, 5 .0, 6 .0, 7 .4, 8 .0  or 9.0, in a final volume of 1 mI. The reaction was started by the 
addition of p-nitrophenyl acetate to a final concentration of 0 .2  roM and incubated at 37°C 
for 5 minutes and the release of p-nitrophenol was monitored at 400 nm. The data was 
graphed as specific activity (nrnoles/hr/llg) vs. pH. 
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Figure 17:  pH Optima curve of the hydrolysis of p-nitrophenyl caprylate by the purified 
recombinant lung carboxylesterase. The purified carboxyl esterase (7 Ilg) was diluted with 
200 mM phosphate buffer, 5 mM �-mercaptoethanol and 80 mM potassium chloride at pH 
4.0, 5 .0, 6 .0, 7 .4, 8 .0  or 9 .0, in a final volume of I mi. The reaction was started by the 
addition ofp-nitrophenyl caprylate to a final concentration ofO.2 mM and incubated at 37°C 
for 1 5  minutes and the release of p-nitrophenol was monitored at 400 nm. The data was 
graphed as specific activity (nmoles/hr/llg) vs. pH. 
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caprylate, respectively. The pH optima for both substrates is 7 .4.  
Site-directed mutagenesis of the lung carboxylesterase eDNA 
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The wild type lung carboxyl esterase and the liver CEH share a 99% cDNA sequence 
similarity and a 99% amino acid similarity, yet their respective substrate specificities are very 
different. The lung carboxyl esterase has a higher specific activity towards the more water 
soluble p-nitrophenyl acetate than towards the 8 carbon-chain p-nitrophenyl caprylate. The 
liver CEH demonstrates a higher specific activity towards the more hydrophobic p-nitrophenyl 
caprylate than towards the 2 carbon-chain p-nitrophenyl acetate. Furthermore, the lung 
carboxylesterase shows no detectable activity towards the hydrophobic substrate cholesterol 
oleate, whereas the liver CEH does hydrolyze the hydrophobic substrate cholesterol oleate. 
In order to determine the important residue or residues responsible for the differences 
in specific activity, the six amino acid residue differences (Table 5) between the two proteins 
were mutated one by one in a cumulative fashion with each successive mutation contain1ng 
all of the previous mutations. Four transition point mutations and two transversion point 
mutations were made in the lung carboxyl esterase cDNA. The order of the point mutations 
and their corresponding amino acid changes were as follows: Mutation I :  nucleotide 557, A 
to G, Gin to Arg (Q I 86R); Mutation 2: nucleotide 1 3 3 1 ,  C to T, Thr to Met (T444M); 
Mutation 3 :  nucleotide 1 474, A to C, Lys to Gin (K492Q); Mutation 4: nucleotide 1472, 
G to C, Ser to Thr (S49 I T); Mutation 5 :  nucleotide 1 269, G to A, Met to lie (M423 I); 
Mutation 6: nucleotide 1 5 1 7, A to G, Asn to Ser (N506S). Mutant plasmids were 
transfected into Cos-7 cells and assayed for enzymatic activity towards p-nitrophenyl acetate, 
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Table 5: Sequence differences between rat hepatic cholesteryl ester hydrolase(CEH) and rat 













430 TIG GT A GTG438 
* 
466 GTC CTC TGC414 
* 
466 GTI CTC TCT'74 
516 CGG GGC AAC164 
* 
516 CAG GGC AAC164 
1 192 GCT GAG AAGI200 
* 
1 1 92 GCC GAG AAGI200 
1267 AT A TIT GGT1275 
* 
1 267 ATG TIT GGT1275 











1 285 GT A ATG GTG TCT CGA AGTI302 
1n9 
1n9 
1 330 ATG TAT GAAI338 
* 




1 5 1 6  
ACC CAA ATG1479 
* * 
AGC AAA ATGI479 
AGC CCT AATI524 
* 
AAC CCT AA TI 524 
AAG CT A AAG GGG AAG 1743 
* * 
GAG CT A AAG GGG AA 1 742 
• indicates difference in sequence 
Amino Acid Sequence Change 
R G N  
* 
Q G N  
I F G 
* 
M F G  
M Y E  
* 
T Y E  
TQ M 
* * 
S K M  
S P N  
* 
N P N  
No change in amino acid sequence 
No change in amino acid sequence 
Basic to polar, uncharged 
No change in amino acid sequence 
Conserved 
No change in amino acid sequence. 
Nonpolar to polar, uncharged 
Conserved/uncharged to basic 
Conserved 
No change in amino acid sequence 
89 
p-nitrophenyl caprylate and cholesterol oleate. 
Figure 1 8  shows the changes in specific activities of each mutation towards p­
nitrophenyl acetate, p-nitrophenyl caprylate and cholesterol oleate. The specific activity 
towards the water soluble p-nitrophenyl acetate is greatly reduced after the first mutation and 
is completely knocked out after the second mutation. It increases after the third mutation and 
the fourth mutation but remains below the wild type lung carboxylesterase level. The final 
mutation to liver CEH exhibits a much lower specific activity towards p-nitrophenyl acetate 
than the lung carboxylesterase. The specific activity towards the more hydrophobic p­
nitro phenyl caprylate remains the same as the lung carboxyl esterase after the first mutation 
and increases after the second mutation. After the third mutation, the specific activity 
decreases to the level of the lung carboxyl esterase, but increases almost 2-fold after the fourth 
mutation. The fifth mutation produces the highest specific activity towards p-nitrophenyl 
caprylate, increasing about 5300% over the lung carboxyl esterase level. This is reduced after 
the final mutation to CEH but remains well above the level demonstrated by the lung 
carboxylesterase. In the wild type lung carboxyl esterase and the first three mutatants, there 
is no detectable activity towards the hydrophobic substrate cholesterol oleate. However, a 
measurable specific activity is shown after the fourth mutation and increases consistantly after 
the fifth mutation and the sixth to CEH. The importance of this data is not in the specific 
values of the measured specific activities towards the different substrates, but in the general 
trends that are demonstrated as the mutations progress from the lung carboxyesterase to the 
liver CEH. 
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Figure 18 :  Specific activities of the lung carboxylesterase mutants towards p-nitrophenyl 
acetate, p-nitrophenyl caprylate and cholesterol oleate. Four transition point mutations and 
two transversion point mutations were made in the lung carboxylesterase cDNA. The order 
of the point mutations and their corresponding amino acid changes were as follows: Mutation 
I: nucleotide 557, A to G, Gin to Arg; Mutation 2: nucleotide 1 3 3 1 ,  C to T, Thr to Met; 
Mutation 3 :  nucleotide 1 474, A to C, Lys to Gin; Mutation 4: nucleotide 1 472, G to C, Ser 
to Thr; Mutation 5 nucleotide 1 269, G to A., Met to lie; Mutation 6 (CEH): nucleotide 
1 5 1 7, A to G, Asn to Ser. Mutant plasmids were transfected into Cos-7 cells and assayed for 
enzymatic activity towards p-nitrophenyl acetate, p-nitrophenyl caprylate and cholesterol 
oleate. nd = not detectable. 
�-.s; � +=< ......... u ... < .c:: 
u Us .- Q) -
.- � � c:  00 -
2600J 1 
600 
500 500 �-.s; � +=< ......... u ... 
400 400 < .c:: u Us 
.- Q) 
- -
300 300 .- � � a.  
200 200 00 -
1 00  1 00  
0 0 
PNPA PNPC Xol-Oleate 
1 C:::=I ====, 2 3 4 -- 5 
Lung CE C:::=I ===::::JI Liver CEH 
9 1  
92 
Figure 1 9  shows the ratio of specific activity towards the more hydrophobic p­
nitro phenyl caprylate to the water soluble p-nitrophenyl acetate. The trend from the lung 
carboxylesterase to the liver CEH shows a resultant shift in specificity from the hydrophilic 
p-nitrophenyl acetate to the more hydrophobic p-nitophenyl caprylate. Figure 20 shows the 
ratio of the specific activity towards the hydrophobic cholesterol oleate to the water soluble 
p-nitrophenyl acetate. After mutation 4 there is the first detectable specific activity towards 
cholesterol oleate and this increases after the fifth mutation and again after the sixth mutation 
to CEH. This data further supports the resultant shift in specificity from hydrophilic to 
hydrophobic substrates. The trends in specificity towards more hydrophobic substrates are 
confirmed by the actual measured specific activities ofthe recombinant proteins towards each 
of the three substrates (Figure 2 1 ) . 
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Figure 19 :  Ratio of specific activity (nmoles/hr/Jlg) of the lung carboxyl esterase mutants 
towards p-nitrophenyl caprylate to specific acivity of the lung carboxyl esterase mutants 
towards p-nitrophenyl acetate. The order of the point mutations and their corresponding 
amino acid changes were as follows: Mutation I :  nucleotide 557, A to G, GIn to Arg; 
Mutation 2: nucleotide 1 3 3 1 ,  C to T, Thr to Met; Mutation 3 :  nucleotide 1 474, A to C, Lys 
to GIn; Mutation 4: nucleotide 1 472, G to C, Ser to Thr; Mutation 5 :  nucleotide 1 269, G 
to A, Met to lie; Mutation 6 (CEH): nucleotide 1 5 1 7, A to G, Asn to Ser. Mutant plasmids 
were transfected into Cos-7 cells and assayed for enzymatic activity towards p-nitrophenyl 
acetate and p-nitrophenyl caprylate. ' 
94 
80 
� 70 oS; < 60 +:. a.. 50 o z < a.. 40 o ° ° 
0- (J � a.. 30 O z <U a.. 20 Q. 
en 1 0  
0 
CE 1 2 3 4 5 CEH 
95 
Figure 20: Ratio of specific activity (nmoleslhr/!lg) of the lung carboxylesterase mutants 
towards cholesterol oleate to specific acivity of the lung carboxylesterase mutants towards 
p-nitrophenyl acetate. The order of the point mutations and their corresponding amino acid 
changes were as follows : Mutation I :  nucleotide 557, A to G, Gin to Arg; Mutation 2 :  
nucleotide 1 3 3 1 ,  C to T, Thr to Met; Mutation 3 :  nucleotide 1 474, A to C, Lys to Gin; 
Mutation 4: nucleotide 1 472, G to C, Ser to Thr; Mutation 5 :  nucleotide 1 269, G to A, Met 
to lie; Mutation 6 (CEH): nucleotide 1 5 1 7, A to G, Asn to Ser. Mutant plasrnids were 
transfected into Cos-7 cells and assayed for enzymatic activity towards p-nitrophenyl acetate 
and cholesterol oleate. ' 
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Figure 2 1 :  Specific Activities of purified recombinant lung carboxyl esterase and liver CEH 
towards p-nitrophenyl acetate, p-nitrophenyl caprylate and cholesterol oleate. 8 Ilg of sample 
protein was diluted with 200mM phosphate buffer, 5mM �-mercaptoethanol and 80 mM 
potassium chloride, in a final volume of I mI. The reaction was started by the addition of p­
nitrophenyl acetate or p-nitrophenyl caprylate to a final concentration of 0.2mM and 
incubated at 3 7°C for 5 minutes for p-nitrophenyl acetate or 1 5  minutes for p-nitrophenyl 
caprylate. The release of p-nitrophenol was monitored at 400 nm. The specific activities 
towards p-nitrophenyl acetate and p-nitrophenyl caprylate were measured as nmoleslhr./mg. 
To measure specific activity towards cholesterol oleate, 8 Ilg of sample protein was added 
to the assay buffer and the reaction was started by the addition of 75 IlM cholesteryl [ 1 _14C] 
oleate (New England Nuclear, Boston, MA) with specific radioactivity of 1 2,000- 1 3 ,000 
dpmlnmole. The reaction mixture was incubated for 30 minutes at 37°C and then stopped by 
the addition of3 .25 ml ofmethanol :choroform:hexane (3 .85 :3 .42 :2 .73) v/v/v and 50 III of 1M 
NaOH. The tubes were vortexed and phases separated by centrifugation. A 1 m l  aliquot of 
the aqueous phase was transferred to a scintillation vial and the associated radioactivIty will 
be determined. The specific activities towards cholesterol oleate were measured as 
pmoles/hr.lmg. 
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This dissertation describes the characterization of a novel pulmonary carboxylesterase. 
Firstly, it describes the molecular cloning, sequencing and expression of the cDNA. Secondly, 
it establishes the localization of the corresponding mRNA in lung tissue, and offers a potential 
role that it may play in xenobiotic metabolism. Thirdly, it describes the over-expression of 
the recombinant protein using a baculovirus system, and the characterization of a single gene 
product from the highly homologous carboxyl esterase family of proteins. Lastly, this 
dissertation shows that very few amino acid differences between two carboxylesterases may 
lead to very different substrate specificities. Two carboxylesterases, hepatic CEH and the 
pulmonary carboxylesterase described here, have been cloned and purified in this laboratory. 
There is a 99% sequence similarity between these two proteins, yet the lung enzyme 
hydrolyzes hydrophilic substrates with greater activity than hydrophobic substrates, while the 
liver enzyme hydrolyzes both hydrophilic and hydrophobic substrates. As the pulmonary 
carboxyl esterase is mutated to the hepatic CEH, there is a clear shift in specificity from 
hydrophilic to hydrophobic substrates, which is supported by the specific activities of both 
recombinant proteins with the various substrates. 
Comparisons between the rat pulmonary carboxyl esterase and other published 
carboxyl esterase sequences show that the pulmonary carboxyl esterase reported here is very 
99 
1 00 
closely related to hepatic CEH, pI 6. 1 esterase and hydrolase A. A search of the GenEMBL 
database revealed 99.6%, 99.3% and 99.5% identity of the rat lung carboxylesterase cDNA 
to hepatic CEH (Ghosh et ai, 1 995), hydrolase A (Yan et ai, 1 995) and pI 6. 1 (Robbi et ai, 
1 990) esterase, respectively. In contrast, the rat lung carboxylesterase cDNA exhibits 
72.9%, 73 .9% and 73 .2% identity to hydrolase B (Yan et ai, 1 994), hydrolase C (Yan et ai, 
1 995) and ES-4 (Robbi et ai, 1 996), respectively. This pattern of identities suggests the 
existence of two subfamilies of carboxylesterases: subfamily 1 which includes lung 
carboxylesterase, hepatic CEH, pI 6. 1 esterase and hydrolase A, and subfamily 2 which 
includes hydrolase B, hydrolase C and ES-4 . Whereas identity is high within each subfamily, 
the similarities between the subfamilies are only on the order of 73%. 
The amino acid sequence translated from the cDNA reported here (Figure 2) exhibits 
1 00% identity with the first 1 9  N-terminal amino acids of the principal carboxylesterase in the 
rat lung purified by Gaustad et al (Gaustad et ai, 1 99 1 ) . In contrast to reported subcellular 
distribution of rat hepatic carboxylesterases, the rat pulmonary carboxyl esterase purified by 
Gaustad et al was shown to be predominantly in the cytosolic fraction whereas negligible 
activity was present in the micro somes (Gaustad et ai, 1 99 1 ). Preliminary results show that 
the pulmonary carboxyl esterase described here is also found in the cytosolic fraction. 
Therefore, the pulmonary carboxyl esterase cDNA reported here probably encodes the 
cytosolic carboxylesterase characterized by Gaustad et al. 
Carboxylesterases belong to the family of serine esterases, which are characterized by 
a conserved catalytic triad (serine, histidine and an acidic residue). As shown in Table 3 ,  
1 0 1  
domains associated with the catalytic triad are present in the pulmonary carboxylesterase. 
These conserved regions contain putative active site residues, namely ASpl l S in a SEDCL Y 
motif, Ser21 in a GXSXG motif, Glu246 in an SES motif, and HiS466 in a GDHGD motif (Yan 
et ai, 1 994). Furthermore, four cysteine residues in the lung carboxyl esterase correspond to 
the four cysteine residues of the hepatic CEH (Ghosh et ai, 1 995), pI 6 . 1 esterase (Robbi et 
ai, 1 990), hydrolase A (Yan et ai, 1 995) and torpedo acetylcholinesterase (Schumacher el ai, 
1 986). It has been demonstrated that these cysteines pair to form internal disulfide bridges 
in human cholinesterase (Lockridge et ai, 1 987). In addition to these four cysteine residues, 
hydrolase B (Yan et ai, 1 994) and ES-4 (Robbi et ai, 1 996) contain a fifth cysteine and 
hydrolase C (Yan et ai, 1 995) contains a sixth cysteine not present in the lung 
carboxyl esterase. 
It has been shown that N-glycosylation can have a profound effect on the spe-cific 
activity of proteins (Kroetz et ai, 1 993) .  Kroetz et al found that a glycosylated hepatic 
carboxyl esterase demonstrated higher a specific activity than its nonglycosylated counterpart. 
The lung carboxylesterase described here shares two potential N-glycosylation sites with pI 
6 . 1 esterase (Robbi et aI, 1 990) and CEH (Ghosh et aI, 1 995).  Asn79 and Asn489 of the lung 
carboxyl esterase and CEH corresponds to Asn61 and Asn47 1 ,  respectively in pI 6 . 1 esterase. 
CEH contains one additional potential N-glycosylation site at Asn504 not present in the lung 
carboxylesterase (Ghosh et aI, 1 995) which might contribute to differences in substrate 
specificity. Hydrolase B (Yan et ai, 1 994), hydrolase C (Yan el aI, 1 995) and Es-4 (Robbi 
el ai, 1 996) all contain one potential N-glycosylation site similar to the lung carboxylesterase 
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at Asn61 It has been reported that Asn1 of the hydrolase B (Yan et ai, 1 994) and hydrolase 
C (Yan et ai, 1 995) is a potential N-glycosylation site. However, due to the position of the 
proline residue in the motif Asn-Xaa-Ser/Thr where Xaa is proline, it is highly unlikely that 
Asn1 of these sequences is glycosylated (Bause, 1 983) .  
The relationship between the pulmonary carboxylesterase reported here and other 
carboxylesterases is fu rther confirmed by expression of the active enzyme. As shown in 
Figure 4, extracts from Cos-7 cells transfected with the lung carboxyl esterase cDNA exhibited 
a 4-fold increase in activity towards p-nitrophenyl acetate and a 5 . 5-fold increase in activity 
towards p-nitrophenyl caprylate. p-nitrophenyl acetate and p-nitrophenyl caprylate are the 
substrates often used to confirm the expression of active carboxylesterases. Furthermore, no 
activity towards cholesterol oleate was detectable in extracts from Cos-7 cells transfected 
with the lung carboxyl esterase cDNA. It should be noted, Cos-7 cells were used because of 
negligible endogenous carboxyl esterase activity. Furthermore Cos-7 express T -antigen which 
allows for replication of the transfected plasmid. 
From the viewpoint of pharmacology and toxicology, the tissue carboxylesterase that 
first encounters an organophosphorus compound is primarily responsible for its detoxification 
(Maxwell et ai, 1 987). Among all tissues that are permanently exposed to the environment, 
the lung provides the largest surface of primary contact with air contaminated with xenobiotic 
vapors, aerosols and particles (Foth, 1 995). Therefore, the pulmonary carboxyl esterase may 
serve as the primary detoxifying enzyme against inhaled organophosphorus agents. The 
results from this study indicate the presence of a lung carboxylesterase in the epithelial lining 
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of the small diameter airway at the terminal bronchiole level (Figure 6) where it would come 
in direct contact with, and be able to inhibit the effects of, inhaled organophosphorus agents. 
Organophosphorus compounds are highly toxic ester derivatives of phosphoric and 
phosphonic acid, that elicit their primary effects by phosphorylating or phosphonylating the 
serine hydroxyl at the active site of acetylcholinesterase (Gray, 1 984). It has been shown that 
organophosphorus compounds react irreversibly with the active site serine of 
carboxylesterases in a similar manner as acetylcholinesterase in a I :  I stoichiometry, and the 
resulting inhibition produces no physiological toxicity (Junge and Kirsch, 1 975). Therefore, 
carboxyl est erases act as scavengers that reduce the amount of organophosphorus compound 
available to inhibit acetylcholinesterase The detoxification of the more toxic 
organophosphorus agents such as soman is primarily carried out by the lung and plasma 
carboxylesterases. Moreover, when carboxyl esterase activity is inhibited prior to 
organophosphorus poisoning, the lethality of the effects are markedly potentiated (Maxwell 
et ai, 1 987). As shown in Figure 7 there is a total inhibition of the lung carboxylesterase by 
the organophosphorus agent paraoxon at a concentration of 0. 1 J.l.M after a 30  min. incubation 
indicating the possible role this protein could play in scavenging these toxic agents, thereby 
reducing their lethality. 
The kinetic data obtained for the recombinant pulmonary carboxyl esterase described 
in this dissertation was compared with the available kinetic data of other carboxylesterases. 
Comparisons made between the KM and V max for the purified recombinant pulmonary 
carboxyl esterase and other carboxylesterases are described in Table 4. The V max calculated 
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for the pulmonary carboxylesterase described here is similar to the V rna., reported by Gaustad 
et al. However, the KM values of the two pulmonary carboxylesterases differ substantially 
(Table 4 and Table 2). This is probably due to the fact that the recombinant lung 
carboxylesterase described here is a single gene product, and the protein described by Gaustad 
et al was conventionally purified and, in all likelihood, is a heterogenous mixture of 
carboxylesterases due to their high homology and similar characteristics. Furthermore, the 
V max of the purified recombinant protein described here is comparable to the V max 
determinations for the lung carboxylesterase described by Gaustad et al (Gaustad et ai, 1 99 1 )  
and hydrolase A and B described by Morgan et al (Morgan et ai, 1 994), indicating that these 
carboxylesterases hydrolyze the water soluble p-nitophenyl acetate at a similar rate. 
However, comparisons made between the kinetic data of the pulmonary carboxyl esterase 
described here and the available kinetic data of other carboxylesterases is l imited because the 
pulmonary carboxyl esterase is the only recombinant carboxylesterase in the literature. ' The 
respective kinetic parameters that serve as a basis for comparison were obtained from 
conventionally purified caboxylesterases; therefore, definitive comparisons are problematic 
to make. 
The carboxylesterases are a highly homologous family of enzymes whose substrate 
specificities often overlap, as is indicated in Table 1 and by the comparison of the enzyme 
kinetics (Gaustad et ai, 1 99 1 ;  Morgan et ai, 1 994). Two members of this family of enzymes, 
the lung carboxyl esterase described here and the liver CEH previously described in this 
laboratory, share a 99% identity in both cDNA and amino acid sequences. Despite almost 
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identical sequences, these proteins have very different substrate specificities. The lung 
carboxyl esterase hydrolyzes hydrophilic substrates but not hydrophobic substrates. On the 
other hand, the liver CEH hydrolyzes both hydrophilic and hydrophobic substrates. 
Therefore, the six amino acid differences between the two proteins are the focus of attention 
as they seemingly confer the very different enzymatic activities. Site-directed mutagenesis 
was used to cumulatively mutate the cDNA of the lung carboxylesterase to the cDNA of the 
liver CEH. Each mutant plasmid was transfected into Cos-7 cells and the enzymatic activity 
towards p-nitrophenyl acetate, p-nitrophenyl caprylate and cholesterol oleate were measured 
for each one. 
The order of the point mutations and their corresponding amino acid changes were 
as follows: Mutation I :  nucleotide 5 57, A to G, GIn to Arg (Q I 86R); Mutation 2: nucleotide 
1 3 3 1 ,  C to T, Thr to Met (T444M); Mutation 3 :  nucleotide 1 474, A to C, Lys to- Gin 
(K492Q); Mutation 4: nucleotide 1 472, G to C, Ser to Thr (S49 1 T); Mutation 5: nuclebtide 
1 269, G to A., Met to lie (M423I); Mutation 6: nucleotide 1 5 1 7, A to G, Asn to Ser 
(N506S). The following rationale was used in determining the order in which the mutations 
were carried out : First, the substrate specificities of both the wild-type pulmonary 
carboxyl esterase and the wild-type hepatic CEH have been thoroughly characterized . In 
theory, by mutating the differences in a cumulative fashion from the pulmonary sequence to 
the hepatic sequence, the known catalytic activity of the hepatic CEH (the hydrolysis of 
cholesterol oleate) should appear. When this activity is measured, it will determine the 
important regions of the protein responsible for the differences in catalytic activity. Second, 
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the first three residues were non-conserved differences between the sequences, mutated in 
order from 5' to 3 ' .  The second three residues were conserved differences mutated in order 
from 5' to 3 ' .  The non-conserved residues were mutated first because they represent the most 
dramatic differences ( i .e .  positive charge to hydrophobic) between the two wild-type primary 
amino acid sequences. 
The first mutation, Q 1 86R, resulted in the change from a polar uncharged residue to 
a basic residue. This mutation is located 34 residues before the active site serine but, is not 
within any of the consensus sequences of the catalytic triad. The secondary structure of the 
region surrounding this mutation predicted according to Chou-Fasman (Figure 22) yielded 
a dramatic change in the Beta turn in both the wild type and mutated proteins, indicating that 
tertiary structure was affected by this mutation. Figure 1 8  shows the effects that this 
mutation had on catalytic activity. While no activity towards cholesterol oleate was detected 
and no change in activity towards p-nitrophenyl caprylate was measured, there was a 1arge 
decrease in activity towards p-nitrophenyl acetate. As indicated in Figure 22, it appears that 
mutation Q l 86R alters the secondary structure of the protein which may be responsible for 
the observed change in the catalytic activity towards p-nitrophenyl acetate. Therefore, this 
residue is vital for catalytic activity towards water-soluble substrates. 
The second mutation, T444M, resulted in a change from a polar uncharged residue 
to a hydrophobic residue. This mutation was not within any of the consensus sequences of 
the catalytic triad. The secondary structure surrounding this mutation, predicted according 
to Chou-Fasman (Figure 22) indicated a change from a Beta sheet conformation in the wild 
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Figure 22 : Chou-Fasman prediction of the secondary structure of the wild type lung 
carboxyl esterase (panel A) and liver CEH (panel B) with hydrophobicity plot superimposed 
over it (window of 7). Residues with cumulative hydrophobic index of more than 1 . 3 are 
marked with pink diamond. Residues with cumulative hydrophilic index of more than 1 . 3 are 
marked with orange oval. Glycosylation sites are marked with -0. a-helices are shown with 
a sine wave, p-sheets with a sharp-toothed wave, turns with 1 800 turns and random coils-with 








type lung carboxylesterase to an a- helix in the mutated protein (Figure 23) .  Chou-Fasman 
also predicted a large change in the hydrophilicity from 0 .3 1 4  for the threonine in the lung 
carboxyl esterase to -0.057 for the methionine in the mutant protein. As indicated in Figure 
1 8  there is no detectable activity towards cholesterol oleate. The activity towards p­
nitro phenyl acetate is increased but remains below the wild type levels. Furthermore, activity 
towards p-nitrophenyl caprylate is decreased to wild type lung carboxylesterase levels. 
The third mutation, K492Q, resulted in a change from a basic residue with a long 
hydrophobic chain to a polar uncharged residue. This mutation was also not within the 
consensus sequences of the catalytic site of the protein. The secondary structure surrounding 
this mutation predicted according to Chou-Fasman showed an increase in the length ofa Beta 
sheet compared to the wild type protein (Figures 22 and 23). The affects on the catalytic 
activity by this mutation are shown in Figure 1 8 . Again, there is no detectable activity 
towards cholesterol oleate. However, the activity towards p-nitrophenyl caprylate IS 
increased while the activity towards p-nitrophenyl acetate was no longer detectable. 
The fourth mutation, S49 1 T, resulted in the change of a polar, uncharged residue to 
a polar, uncharged residue. Although this represents a conserved mutation, the mutated 
protein contained the bulkier threonine instead of a serine. This mutation is adjacent to 
mutation K492Q and is also not part of the catalytic triad of the wild type lung 
carboxylesterase. The secondary structure around this mutation predicted according to Chou­
Fasman shows an even greater increase in the length of the Beta sheet affected by mutation 
K492Q (Figures 22 and 23) .  Figure 1 8  shows the presence of activity towards cholesterol 
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Figure 23 : Chou-Fasman one dimensional prediction of secondary structure of the lung 
carboxyl esterase (panel A) and liver CEH (panel B): l3-tums, a-helices, l3-sheets and position 
of potential N-glycosylation sites are indicated. 
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oleate for the first time in the series of mutations. TlUs could be affected by the increase in 
size of the Beta sheet from nine residues in the wild type lung carboxylesterase to tlUrteen 
residues in the mutant protein. The activity towards p-nitrophenyl acetate increases but 
remains below wild type lung carboxyl esterase levels, and the activity towards p-nitrophenyl 
caprylate increases well above the wild type levels. 
The fifth mutation, M423 1, resulted in the change of a hydrophobic residue to a 
hydrophobic residue. TlUs mutation was not within the consensus sequences of the active 
site. The secondary structure in the region surrounding tlUs mutation predicted by Chou­
Fasman (Figures 22 and 23) yielded a similar Beta sheet in both the mutated and wild type 
proteins. However, as shown in Figure 1 8, there is a large increase in activity towards 
cholesterol oleate and an even larger increase towards p-nitrophenyl caprylate. Although tlUs 
is considered a conserved mutation, and both functional.groups of metlUonine and isoleucine 
are relatively inert, methionine is the only non-polar amino acid that has an unbranched side 
chain. When this residue is mutated to the branched isoleucine, it is conceivable that the 
bulkier group attributes to the increase in activity seen towards cholesterol oleate and p­
nitrophenyl caprylate. 
The final substitution, N 506S, represented the change of a polar uncharged residue 
to a polar uncharged residue. The product of this mutation is liver CEH. TlUs mutation is 
not witlUn the consensus sequences of the catalytic triad of the lung carboxyl esterase or the 
liver CEH. The secondary structure in the region surrounding tlUs mutation predicted by 
Chou-Fasman (Figures 22 and 23) yielded a more ambiguous Beta tum in the mutated protein 
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than in that predicted for the wild type protein. Figure 1 8  shows an even greater increase in 
activity towards cholesterol oleate than any other mutation. The activity towards p­
nitrophenyl caprylate decreases, but remains well above the levels seen in the lung 
carboxyl esterase. Furthermore, the activity towards p-nitrophenyl acetate decreases further 
to levels well below those seen in the lung carboxylesterase. It is notable to point out that 
Asn504 is a potential N-glycosylation site in the hepatic CEH but not in the pulmonary 
carboxylesterase. The mutation N506S alters the potential N-glycosylation site at residue 
504. The introduction of a serine at position 506 completes the glycosylation motif, Asn504_ 
Xaa-Ser506, enabling Asn504 to be glycosylated. This change, seemingly, is responsible for a 
large increase in activity towards cholesterol oleate. 
Five of the six mutations analyzed produce changes in the predicted secondary 
structure of the lung carboxylesterase. The two dimensional protein secondary structure as 
predicted by Chou-Fasman (Figure 22) of the lung carboxyl esterase and liver CEH differ in 
two significant regions that coincide with the major differences in substrate specificities. At 
mutation Q 1 86R there is a dramatic decrease in activity towards the water soluble substrate 
p-nitrophenyl actetate. The comparisons between the lung carboxyl esterase (panel A, Figure 
22) and liver CEH (panel B, Figure 22) at amino acid residue 1 86 shows a dramatic difference 
in the secondary structure of the proteins. The mutation from an uncharged glutamine in the 
lung sequence to a positively charged arginine in the liver sequence has a significant effect on 
the secondary structure in addition to the catalytic activity towards water soluble substrates. 
The second region where there is a difference between the lung carboxyl esterase and the liver 
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CEH is around amino acid residue 500 (Figure 22). Mutations K492Q, S49 1 T  and N506S 
confer a change in the secondary structure as predicted by Chou-Fasman. As indicated in 
panel A of Figure 22, the Beta sheet around amino acid residue 500 of the lung sequence is 
larger than that seen in the same area of the liver sequence (panel B, Figure 22). This area 
of the protein seems to be vital for catalytic activity towards hydrophobic substrates. Activity 
towards cholesterol oleate is not detectable after mutation K492Q, however the length of the 
Beta sheet is increased. It increases further after mutation S49 1 T and there is a large 
measurable increase in activity towards cholesterol oleate. The activity towards cholesterol 
oleate increases still further after N506S, possibly due to the appearance of a potential N­
glycosylation site at Asn504. There are some major differences in this area between the two 
proteins. There is a positively charged lysine in the lung carboxylesterase where there is a 
polar, but uncharged glutamine in the liver CEH. This change in sign could have an effect on 
the interaction with hydrophobic substrates. The other significant difference between the two 
proteins in this region around amino acid 500 is that the liver CEH has an additional predicted 
glycosylation site in this region (Figure 23, panel B). Glycosylation has been shown to have 
significant effects on the catalytic activities of proteins (Busca et ai, 1 995), and it is important 
to stress that this difference between the lung and the liver proteins could play a major role 
in the ability of the liver enzyme to hydrolyze hydrophobic substrates, and to further explain 
why the lung enzyme cannot hydrolyze hydrophobic substrates. 
Figure 23 shows the one dimensional graphical output of the secondary structure of 
the lung carboxylesterase and the liver CEH as predicted by Chou-Fasman. Panel A and panel 
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B show the predicted Beta tum structure, a-helical structure, the Beta sheet structure and the 
potential glycosylation sites of the lung protein and the liver protein. There are two regions 
where there are noticeable differences between the structures of the lung protein and the liver 
protein that supports the two dimensional prediction shown in Figure 22. 
The first is the Beta turn around amino acid residue 1 86. This change in secondary 
structure is a direct result of mutation Q 1 86R. It was this mutation that produced a dramatic 
decrease in the activity towards hydrophilic substrates, yet had no effect on the activity 
towards hydrophobic substrates. This indicates that the glutamine 1 86 in the lung 
carboxylesterase is potentially important for activity towards hydrophilic substrates. The 
second structural difference is the region around amino acid residue 500. Panel A and B of 
Figure 23 show a difference in the Beta turn at this position. Furthermore there is a difference 
in helical structure and a difference in Beta sheet structure between the two proteins. -This 
corroborating data, which is consistent with the two dimensional structural prediction in 
Figure 22, indicates that the area around amino acid 500, more specifically, threonine 49 1 ,  
glutamine 492 and serine 506 of the liver CEH i s  vital for catalytic activity towards 
hydrophobic substrates. 
Further corroborating evidence is shown in Figure 24. This figure shows the 
differences in the predicted helical hydrophobic moments between the lung carboxylesterase 
(panel A) and the liver CEH (panel B). The hydrophobic moment is the hydrophobicity of 
a peptide measured for different angles of rotation per residue. The moment helps recognize 
amphiphilic structures by identifying when residues on one side of the structure are more 
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hydrophobic than on the other (Eisenberg et aI, 1 984). The graphical prediction in Figure 24 
is a measurement of the probability that the peptide at any particular position is located at the 
interface between the interior of the protein and the surface, or more exactly, that the peptide 
separates hydrophobic and hydrophilic regions. As indicated in Figure 24, there are two 
regions of the lung protein and the liver protein that are significantly different . The first is at 
amino acid residue 1 86 .  Panel B of Figure 24 shows the appearance of an amphiphilic region 
at this position of 200 and 1 400 rotation in the liver CEH that is not present in the lung 
carboxyl esterase (panel A, Figure 24). This indicates that mutation Q 1 86R which introduces 
a positively charged lysine is creating an amphiphilic region which may be causing the 
dramatic decrease in catalytic activity towards water soluble substrates. The second region 
where there is a difference in the hydrophobic moments of the two proteins is around the 
region of amino acid residue 500. Panel B, Figure 24 'shows the absence of an amphiphilic 
region that is present in the lung carboxylesterase (panel A, Figure 24). This diffe'rence 
between the two proteins is further corroboration that this region is potentially vital for 
catalytic activity towards hydrophobic substrates. 
It has been shown in lipases that their capacity to hydrolyze hydrophobic substrates 
is directly controlled by a region at the C-terminus of the protein that is necessary for lipid 
binding and hydrolysis (Dugi et ai, 1 992). The presence of a lipid binding pocket and a lipid 
binding pocket "lid" has also been shown to be crucial for activity towards hydrophobic 
substrates (van Tilbeurgh et aI, 1 994; Cordle and Lowe, 1 998). The liver CEH is reported 
to have a lipid binding pocket between cysteine 87 and cysteine 1 1 6, and when this binding 
1 1 7 
Figure 24 : Map of predicted helical hydrophobic moments of lung carboxyl esterase (panel 
A) and liver CEH (panel B). Boxed regions represent differences in the predicted helical 
hydrophobic moments between the lung carboxylesterase and the liver CEH The 
hydrophobic moment is the hydrophobicity of a peptide measured for different angles of 
rotation per residue. The moment helps recognize amphiphilic structures by identifying when 
residues on one side of the structure are more hydrophobic than on the other (Eisenberg et 
ai, 1 984). The graphical prediction is a measurement of the probability that the peptide at any 
particular position is located at the interface between the interior of the protein and the 
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pocket is cleaved by mild trypsin digestion activity towards hydrophobic substrates is lost 
(Natarajan et ai, 1 996). The pulmonary carboxylesterase described here shares 1 00% identity 
with the liver CEH within this lipid binding loop region. Therefore, it is tempting to speculate 
that the region around amino acid residue 500 in the lung carboxylesterase creates a C­
terminal "lid" that prevents the interaction of hydrophobic substrates with the lipid binding 
loop. 
The fact that dramatic differences in catalytic activities between the lung 
carboxylesterase and the liver CEH result from single amino acid mutations is supported by 
the hydrolytic activities of the purified recombinant proteins. The specific activity of the 
purified recombinant lung carboxyl esterase towards p-nitrophenyl acetate is 283 ,000 
nmoles/hr/mg and towards p-nitrophenyl caprylate is 1 8,000 nmoles/hr/mg. Furthermore, the 
purified recombinant lung carboxyl esterase shows no detectable activity towards cholesterol 
oleate. In contrast, the specific activity of the purified recombinant liver CEH towards p­
nitrophenyl acetate is 8,229 nmoleslhr/mg and towards p-nitrophenyl caprylate is 1 99,3 7 1  
nmoles/hr/mg. Furthermore, purified liver CEH does hydrolyze the hydrophobic substrate 
cholesterol oleate with a specific activity of 1 . 53  nmoleslhr/mg. 
In this dissertation, a novel pulmonary carboxyl esterase was cloned, expressed and 
localized to the epithelial lining of the pulmonary airways, and its potential role in the 
detoxification of organophosphorus compounds was substantiated. Furthermore, it was 
shown that although this highly homologous family of proteins shares as much as 99% 
identity, the individual proteins can have very different substrate specificities. It was shown 
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that the purified recombinant lung carboxyl esterase has a greater catalytic activity towards 
hydrophilic substrates. The liver CEH, a carboxyl esterase that shares 99% identity with the 
lung protein, has a greater activity towards more hydrophobic substrates. Through mutational 
analysis of the lung carboxylesterase cDNA, it was shown that two potential regions of the 
protein apart from the catalytic triad confer the differential catalytic activities that exist 
between it and the liver CEH. First, glutamine 1 86 may play a role in the catalytic activity 
towards water soluble substrates. And second, serine 49 1 ,  lysine 492 and asparagine 506 may 
be responsible for the absence of catalytic activity towards hydrophobic substrates, possibly 
forming a C-terminal "lid" that blocks access to a hydrophobic binding site. 
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